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ABSTRACT 
The RET gene encodes a transmembrane tyrosine kinase, that plays a crucial 
role in regulating cell proliferation, migration, differentiation, and survival. 
Activating mutations in RET lead to the development of several inherited and 
sporadic neoplastic diseases. Germline point mutations in RET are responsible 
for multiple endocrine neoplasia (MEN) type 2 and familial medullary thyroid 
carcinoma. Somatic rearrangements of RET have been identified in papillary 
thyroid carcinoma. This makes RET an excellent candidate for the design of 
molecular targeted cancer therapy. The success of imatinib in the treatment of 
patients affected by chronic myelogenous leukemia (CML) has demonstrated 
the power of small molecule kinase inhibitors in cancer therapy. However, 
molecular resistance to these compounds has emerged as a major drawback of 
this approach. Here, we have studied mechanisms of RET resistance to small 
molecule kinase inhibitors. We show that most oncogenic RET mutants are 
highly susceptible to ATP-competitive inhibitors like PP1 and ZD6474. 
However, the change of leucine or methionine residues for valine 804 or the 
change of a cysteine for tyrosine 806 in the RET kinase domain cause 
resistance to these compounds. In particular, the residue corresponding to V804 
in RET is often called “gate-keeper” as it dictates susceptibility of ABL and 
several other kinases to specific inhibitors. Thus, we have searched for 
additional RET kinase inhibitors. Here, we demonstrate that the biaryl urea 
BAY 43-9006 (sorafenib), a multi-targeted ATP-competitive inhibitor, blocks 
RET kinase function and oncogenic activity. Importantly, BAY 43-9006 
inhibited also V804M, V804L and Y806C RET mutants. We show also that the 
capability of BAY 43-9006 of targeting gate-keeper mutants is not limited to 
RET. Indeed, BAY 43-9006 is also an effective inhibitor of PDGFR and KIT 
receptors and here we demonstrate that it is also active against their imatinib-
resistant KIT T670I and PDGFRβ T681I mutants. In conclusion, oncogenic 
kinase mutants might exert resistance to selective small molecule kinase 
inhibitors; a strategy to circumvent this problem might be the use of second line 
inhibitors. Here we demonstrate, that one of such second line inhibitors might 
be BAY 43-9006 that, therefore, holds promise as an anti-cancer agent for the 
treatment of patients carrying RET, KIT and PDGFRβ gate-keeper mutants. 
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1. BACKGROUND 
 
1.1 Protein tyrosine kinases in cancer  
Intercellular communication is critical in embryonic development, as well as 
systemic responses to wounds and infections. In order to carry out these 
communication cascades, nature has created numerous molecules. Protein 
kinases belong to the category of molecules equipped to carry out such cellular 
communications. The major classes of protein kinases include tyrosine kinases 
(TKs), Serine/Threonine Kinase (S/TKs) and dual specificity kinases (Blume-
Jensen and Hunter 2001). While S/TKs act on both serine and threonine, TKs 
act solely on tyrosine. Protein kinases constitute about 1.7% of all the human 
genes (Manning et al. 2002), and nearly all of them are involved in growth 
signaling (Hunter 1987, Robertson et al. 2000). Human genome sequence 
analysis has identified about 518 protein kinases. TK, in particular, include 
both transmembrane receptor tyrosine kinases (RTK) and non-receptor tyrosine 
kinases (NRTK). Nearly 58 RTK and 32 NRTK have been identified. In 
humans, TKs have been demonstrated to play significant roles in many disease 
states including diabetes, cancer and a wide variety of congenital syndromes 
(Robertson et al. 2000). 
RTKs are positioned in key communication junctions within the cellular 
signaling network, their function being to regulate normal cellular development 
and survival. All RTKs consist of a single transmembrane domain that 
separates the intracellular tyrosine kinase region from the extracellular portion 
(Ullrich and Schlessinger 1990). Activation of RTK is typically initiated by 
binding of a ligand (e.g., hormone or growth factor) to a specific site on the 
extracellular domain. Ligand binding induces homodimerization of the 
receptor. Dimerization causes trans-autophosphorylation of the kinase within 
the cytoplasmic domain, releasing auto-inhibitory constraints on the kinase 
(Weiss and Schlessinger 1998). In the inactive form, the kinase subdomains are 
aligned, so that ATP cannot reach the catalytic center of the kinase, the 
autophosphorylation causing the two subdomains of the kinase to shift thereby 
opening the kinase domain for ATP binding. Phosphorylation of tyrosine 
residues on the intracellular kinase domain leads to activation of signaling by 
generating docking sites for SH2 (Src homology 2) and PTB (phosphotyrosine 
binding) domains of effector proteins (Pawson and Scott, 1997). The effectors 
include enzymes (PLC-γ, GAP etc) or adaptor proteins (p85PI-3k, Grb2, etc) 
forming receptor-signalling complexes. Following activation of RTK, several 
transduction pathways can be activated. For instance, activation of PLC gamma 
results in the generation of DAG and IP3 that subsequently activates PKC and 
the release of Ca2+. The activation of Grb2 results in the binding of the GTP  
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exchange factor SOS which facilitates the activation of Ras, the S/TK protein 
kinase Raf-1 and, in turn, the MEK/ERK pathway. Activated RTKs can also 
interact with PI-3 Kinase initiating the PKB/GSK3β/FRAP pathway. Finally, 
some kinases upon activation invoke the JAK/STAT signalling pathway. 
NRTKs include members of the Src, Tec, JAK, Fes, Abl, FAK, Csk, 
and Syk families. They are located in the cytoplasm as well as in the nucleus. 
They exhibit distinct kinase regulation, substrate phosphorylation, and function. 
Deregulation of these kinases has also been linked to several human diseases. 
In most cases, their activation also begins with the phosphorylation of a 
tyrosine residue present in an activation loop. The best studied enzymes in this 
group include Src kinases. Src is believed to be negatively regulated by 
phosphorylation at Tyr527 present at the C-terminus by Csk and other cellular 
kinases. The enzyme assumes an inactive conformation when this 
phosphotyrosine is bound to Src SH2 domain in an intramolecular fashion. In 
this structure, the Src SH3 domain interacts with a single proline, Pro250, in the 
linker region between the SH2 and catalytic domain (Smith and Van Etten 
2001). 
Many tyrosine kinases have been shown to be oncogenic once they have 
lost their regulation. Alterations in significant number of non-receptor tyrosine 
kinases associated with cancers are illustrated in Table 1. Instead, specific 
receptor tyrosine kinases are described thereafter. 
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Table 1: Different families of Non-Receptor Tyrosine Kinases and their 
associations with cancer (Modified from Madhusudhan and Ganesan 
2004). 
 
 
NRTKs 
 
ABL Family                                                                   
ABL1 
ARG 
FRK family 
BRK 
FRK 
SRMS 
JAK Family 
JAK1 
JAK2 
JAK3 
JAK4 
SRC-A Family 
FGR 
FYN 
SRC 
YES1 
SRC-B Family 
BLK 
HCK 
LCK 
LYN 
SYK Family 
SYK 
ZAP70 
FAK Family 
FAK 
PYK2 
ACK Family 
CSK Family 
FES Family 
TEC Family 
Cancer Associations 
 
 
CML, AML, ALL, CMML, 
AML 
  
Breast 
- 
- 
 
Leukaemias 
AML, ALL, T-Cell Childhood ALL, atypical CML 
Leukaemias, B-Cell Malignancies 
- 
 
AML, CLL, EBV-associated Lymphoma 
- 
Colon, Breast, Pancreas, Neuroblastoma 
Colon, Melanoma 
 
- 
- 
T-Cell ALL, CLL 
- 
 
Breast 
- 
 
Adhesion, Invasion and metastasis of several tumors. 
Adhesion, Invasion and metastasis of several tumors. 
- 
- 
- 
- 
 
 
 
Mechanisms of RTK activation in cancer include amplification, gene 
rearrangement and point mutation. Amplification of the proto-oncogene c-
ERBB2 (HER2) is typical of some breast cancers (McCann et al. 1989, Uchino 
et al.1993). Over-expression of HER2 is indeed an adverse prognostic factor in 
human breast cancer (Yu and Hung 2000). EGFR (HER1) overexpression is 
associated with a poor prognosis in ovarian, head and neck, oesophageal, 
cervical, bladder, breast, colorectal, gastric and endometrial cancer 
(Madhusudan and Ganesan 2004). Somatic and germline point mutations are 
commonly responsible for many cancer types. Such mutations up-regulate the 
tyrosine kinase activity, possibly by inducing a dynamic imbalance in favor of 
the active conformation of the kinase (Chiara et al. 2003). This alteration is 
seen in receptors like EGFR (Shu et al. 1990) or MET in selected cases of 
papillary renal carcinoma (Miller et al. 2001). The mechanism of activation of 
RET, KIT and PDGFR tyrosine kinases is described in later sections. Finally, 
rearrangements activate the transforming potential of tyrosine kinases by 
multiple mechanisms. Firstly, the rearrangements remove autoinhibitory 
sequences of the kinase relieving negative constraints. Secondly, by 
substituting its transcriptional promoter with those of the fusion partners, they 
can allow the ectopic expression of tyrosine kinase in cancer cells. Finally, the 
rearrangements generate constitutively active chimeric oncoproteins, which, as 
a consequence of the fusion to heterologus proteins can be forced to dimerize 
and be delocalized to different subcellular compartments with respect to the 
wild type kinase.  
 
 
1.1.1 Abelson (ABL) 
Abelson (ABL) is a non-receptor tyrosine kinase containing nuclear-import and 
-export signals; it undergoes nucleo-cytoplasmic shuttling in proliferating cells. 
The nuclear Abl is activated by DNA damage or tumor necrosis factor to 
promote cell death through transcription-dependent and -independent 
mechanisms (Van Etten et al. 1989, Wang 2000). The BCR/ABL protein 
represents a well known example of an oncogenic molecule formed as a result 
of a chromosomal translocation, which results in the fusion of a part of ABL 
protein, including the tyrosine kinase (TK) domain, to the amino-terminal part 
of the BCR protein (Figure 1). The chromosome resulting from the 
translocation is commonly called Philadelphia chromosome. BCR/ABL is 
present in more than 90% cases of chronic myeloid leukemia (CML) and in a 
portion of acute lymphoblastic leukemia (ALL) cases. The activation of 
BCR/ABL involves phosphorylation at the Y177 residue generating a high-
affinity binding site for growth factor receptor-bound protein 2 (GRB2). GRB2 
binds to BCR/ABL through its SH2 domain and binds to SOS and GRB2-
associated binding protein 2 (GAB2) through its SH3 domains. SOS in turn 
activates RAS. Following phosphorylation by BCR/ABL, GAB2 recruits 
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phosphatidylinositol 3-kinase (PI3K) and SHP2 proteins. The SH2 domain of 
ABL can bind SHC, which, following phosphorylation can also recruit GRB2. 
The ABL SH3 domain and the SH3 binding sites in the carboxy-terminal 
region can bind several proteins that involve regulations of cell 
adhesion/migration. 
 
 
Figure 1 
 
 
 
Figure 1. Schematic representation of BCR/ABL fusion protein, CCOD – Coiled coil domain, 
DH – DBL Homology domain, SH – SRC Homology, NLS- Nuclear localization signals, DNA 
BD – DNA binding domain, AKTIN BD- Actin binding domain, NES- Nuclear exporting 
signal. 
 
 
1.1.2 The platelet derived growth factor receptor 
The observation that fibroblasts proliferate robustly in the presence of serum 
but not plasma led to the discovery of Platelet Derived Growth Factor (PDGF), 
secreted by activated platelets. Platelet–derived growth factor receptors  
(PDGFR) are RTKs. So far the following ligands have been described: PDGF-
AA, PDFG-AB, PDGF-BB, PDGF-CC, and PDGF-DD. These factors exert 
their cellular effects through PDGFRα and PDGFRβ protein tyrosine kinase 
receptors. PDGFRα can be activated by PDGF-AA, PDGF-AB, PDGF-BB, 
and PDGF-CC, whilst PDGF-BB and PDGF-DD bind and activate PDGFRβ. 
PDGFRs play a major role in proliferation, embryonic development, formation 
of connective tissues, and wound healing (Yu et al. 2003). Ligand binding 
induces receptor dimerization, activation and autophosphorylation of the 
tyrosine kinase domain. This in turn recruits SH2 domain containing signal 
transduction proteins and activates signalling enzymes including Src, PI3K, and 
Phospholipase PLCγ (Tallquist and Kazaluaskas 2004) initiating a complex 
network of downstream signalling events, which have yet to be fully 
characterized (Figure 2).  
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Figure 2 
 
 
 
Figure 2. Schematic representation of PDGF receptors: mutations found in different cancers are 
depicted. EXT: extracellular; INT: intracellular. 
 
 
PDGFR are involved in human tumors including glioma, dermatofibrosarcoma, 
neurofibroma, myelomonocytic leukemia, osteoblastoma and osteosarcoma. 
Chronic myelomonocytic leukemia (CMML) is a myelodysplastic syndrome 
characterized by abnormal clonal myeloid proliferation and by progression to 
acute myelogenous leukemia (AML). A subgroup of CMML has been reported 
to have a t (5; 12)(q33; p13) balanced translocation. The consequence of the t 
(5; 12) translocation is expression of a fusion transcript in which the tyrosine 
kinase domain of the PDGFRβ on chromosome 5 is coupled to a ets-like gene, 
tel, on chromosome 12 and this results in constitutively dimerized and activated 
receptors, which drive tumor cell proliferation and survival (Golub et al. 1994). 
Chronic myeloid leukemia (CML) is characterized by the presence of the 
BCR/ABL fusion gene, usually in association with a t (9; 22)(q34; q11) 
chromosomal translocation. Baxter et al. (2002) reported the identification and 
cloning of a rare variant translocation, t (4; 22)(q12; q11), in 2 patients with a 
CML-like myeloproliferative disease. An unusual in-frame BCR/PDGFRα 
fusion mRNA was identified in both patients, with either BCR exon 7 or exon 
12 fused to short BCR intron-derived sequences, which were in turn fused to 
part of PDGFRα exon 12. Sequencing of the genomic breakpoint junctions 
showed that the chromosome 22 breakpoints fell in BCR introns, whereas the 
chromosome 4 breakpoints were within PDGFRα exon 12. Cools et al. (2003) 
demonstrated that idiopathic hypereosinophilic syndrome (HES) is often 
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caused by an interstitial deletion on chromosome 4q12 resulting in fusion of 
PDGFRα and FIP1L1, a neighboring gene. The PDGFRα-FIP1L1 gene is a 
constitutively activated tyrosine kinase that transforms hematopoietic cells and 
is a therapeutic target of imatinib. PDGFRα-FIP1L1 rearrangement was 
identified in 9 of 16 patients with idiopathic hypereosinophilic syndrome and 5 
of 9 patients displayed responses to imatinib that lasted more than 3 months. 
Relapse in one patient correlated with the appearance of a T674I mutation in 
the PDGFRα gene that conferred resistance to imatinib (Cools et al. 2005). In 
the KIT wild type (KIT-WT) gastrointestinal stromal tumor (GIST), 
PDGFRα often has point mutations in the activation loop, causing activation of 
the receptor kinase, which drives tumor cell growth and survival. PDGFRα 
activation loop (exon 18) mutations in the three KIT-WT GISTs that expressed 
phospho PDGFRα were identified. Two of the KIT-WT GISTs had an identical 
PDGFRα missense mutation, leading to substitution of valine for the highly 
conserved aspartic acid at codon 842 (PDGFRα D842V). The other KIT-WT 
GIST had an in-frame deletion, resulting in loss of PDGFRα amino acid 
residues 842 to 845 (DIMH). These PDGFRα mutations are homologous to 
those responsible for KIT and FMS-related tyrosine kinase 3 (FLT3) ligand-
independent kinase activation in human mast cell disorders, acute myeloid 
leukemia, and germ cell (seminoma) tumors (Heinrich et al. 2003).  
 
 
1.1.3 The KIT Receptor 
The receptor for stem cell factor (SCF) KIT is a member of PDGFR family 
receptor tyrosine kinase. Together with its ligand, SCF, KIT is a key 
controlling receptor for a number of cell types including hematopoietic stem 
cells, mast cells, melanocytes, and germ cells. Stimulation of the KIT receptor 
with its ligand results in dimerization of receptors, activation of its intrinsic 
tyrosine kinase activity, and autophosphorylation of KIT on tyrosine residues 
constitute docking sites for Src homology 2 (SH2) domain containing signal 
transduction molecules, which will thereby be recruited to the receptor and 
activated, often through tyrosine phosphorylation (Figure 3). More than 30 
gain-of-function mutations in KIT, either single amino-acid changes or small 
deletions/insertions, have been identified in such highly malignant human 
neoplastic diseases as gastrointestinal stromal tumors (GIST) and mastocytosis. 
GIST mutations cluster in the juxta-membrane region of the receptor, whereas 
most mutations associated to mastocytosis target a specific aspartate residue 
(D816) in the kinase activation loop (Lennartsson et al. 2005) (Figure 3). 
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Figure 3 
 
 
 
 
Figure 3. Schematic representation of the KIT receptor tyrosine kinase. Mutations found in 
different cancer types are depicted.  
 
 
1.2 The RET receptor  
RET was discovered as a novel transforming gene in 1985 by transfection of 
NIH3T3 cells with human lymphoma DNA (Takahashi et al.1985). The 
transforming gene resulted from a recombination event between two unlinked 
DNA sequences, RFP and RET. The recombination occurred during the 
transfection process. Hence, the name RET stands for “rearranged during 
transfection”. The human RET gene lies on chromosome band 10q11.2 
(Ishizaka et al. 1989) and comprises 21 exons. Homologues of RET have been 
identified in higher and lower vertebrates as well as in Drosophila 
Melanogaster  (Hahn and Bishop 2001). RET encodes several protein isoforms 
that are expressed as a result of alternative splicing of mRNA. The larger 
isoform of 1114 amino acids (RET51) contains 51 amino acids at the carboxyl 
terminus that are replaced by 43 amino acids in RET 43 isoform and 9 in RET9 
isoform. The two major isoforms RET51 and RET9 are highly conserved over 
a broad range of species (Carter et al. 2001) (Figure 4). Isoforms RET51 and 
RET9-associated signalling complexes are markedly different, suggesting that 
distinct isoforms can exert different roles (Tsui-Pierchala et al. 2002). Mice 
lacking the long RET isoform (RET51) are normal, whereas mice lacking the 
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short isoform (RET9) have renal malformations and enteric aganglionosis. 
Only RET9 is able to rescue the phenotype of the Ret-null mice (de Graaff et 
al. 2001, Srinivas et al.1999). On the other hand, only RET51 but not RET9 
promotes the survival and tubulogenesis of mouse inner-medullary collecting 
duct cells, suggesting that RET51 signalling may contribute to the 
differentiation during late kidney morphogenesis (Lee et al. 2002). 
 RET acts as receptor for growth factors belonging to the glial cell line 
derived neurotrophic factor (GDNF) family. This family comprises GDNF, 
Neurturin (NTN), Persephin (PSP), and Artemin (ARTN), which all have 
trophic influences on a variety of neuronal populations. These ligands interact 
with multimeric receptors composed by high-affinity glycosyl-
phosphatidylinositol (GPI)- linked receptors and RET kinase. Four GPI linked 
co-receptors have been isolated and designated GFR α 1, 2, 3 and 4. Interaction 
of GDNF, NTN, ARTN and PSP with GFRα1, 2, 3 and 4 respectively can 
promote the dimerization and activation of RET allowing it to transduce 
downstream signals. RET is predominantly expressed in tissues of 
neruroectodermic derivation. In human embryos, RET is expressed in a cranial 
population of neural crest cells, and in the developing nervous and urogenital 
systems. In adults RET expression is found in several neural crest-derived cell 
lines, spleen, thymus, lymph nodes, salivary glands, spermatogonia, and in 
thyroid C cells. In addition RET is normally expressed in the adrenal medulla 
and cerebellum (Takaya et al. 1996). A relatively low amounts of RET mRNA 
can be found in early CD34+ hematopoietic progenitors (Gattei et al. 1997). 
 
 
1.2.1 RET – Structure and function 
RET is a single-pass transmembrane protein, the basic structure of RET is 
similar to other RTKs with extra-cellular, transmembrane portion and intra-
cellular kinase domain. The extra cellular domain of RET has no homology 
with other receptor tyrosine kinases (Takahashi 1988). It contains a cleavable 
signal sequence of 28 amino acids, as well as a conserved cysteine-rich region 
close to the cell membrane. Molecular modeling studies have determined the 
presence of four cadherin – like domains in the extra cellular region (Figure 4). 
These domains participate in calcium binding leading to the stabilization of 
extracellular region (Anders et al. 2001). A single transmembrane domain is 
followed by an evolutionary conserved tyrosine kinase domain interrupted by 
an inter-tyrosine kinase region of 27 amino acids. Similarities have been found 
between the tyrosine kinase domains of RET and those of the subfamily of 
platelet-derived growth factor receptors (Hanks et al. 1988). 
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Figure 4 
 
Figure 4. Schematic structure of the two major RET splicing isoforms, RET51 and RET9. CAD 
– Cadherin domain, CYS – Cysteine-rich domain, TM – Transmembrane domain, TK1 and 2 – 
Tyrosine kinase subdomains. 
 
 
1.2.2 RET Signalling 
The intracellular domain of RET contains at least 12 autophosphorylation sites 
(Liu et al. 1996, Salvatore et al. 2000, Coulpier et al. 2002, Kawamoto et al.  
2004). Sites Tyr1090 and Tyr1096 are present only in the RET51 isoform. 
Interactions of RET with a variety of downstream targets have been identified 
(Figure 5). RET activation affects different downstream targets inside and 
outside lipid rafts, which are special membrane structures of sphingolipids and 
cholesterol packed into moving platforms within the lipid bilayer (reviewed in 
Simons and Ikonen 1997, Ikonen and Simons 1998). Lipid rafts are proposed to 
serve as essential signalling compartments in the cell membrane (Simons and 
Toomre 2000). They are important for cell adhesion, axon guidance and 
synaptic transmission. GPI-anchored proteins, certain transmembrane proteins, 
doubly acylated proteins such as cytoplasmic Src-family kinases, and 
cholesterol-linked and palmitoylated proteins are enriched in the rafts. The 
GFRα proteins, by the virtue of their GPI-anchors, also localise to lipid rafts 
(Poteryaev et al. 1999). 
 Phosphorylated tyrosine residues Tyr905, Tyr981, Tyr1015, and 
Tyr1096 have been identified as docking sites for Grb7/Grb10, Src, 
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phospholipase C-γ (PLC-γ), and Grb2, respectively (Pandey et al.1995, 1996, 
Encinas et al. 2004, Borrello et al.1996, Alberti et al.1998). Phosphorylation of 
Tyr905 stabilizes the active conformation of the kinase and facilitates the 
autophosphorylation of tyrosine residues mainly located in the activation loop 
(Iwashita et al.1996). Tyr1062 acts as a docking site for many adaptor or 
effector proteins: Shc, ShcC, FRS2, IRS1/2, Dok1, Dok4/5, Dok6, Enigma, and 
indirectly for PKCα (Asai et al. 1996, Durick et al. 1996, Arighi et al. 1997, 
Lorenzo et al. 1997, Ohiwa et al. 1997, Hennige et al. 2000, Kurokawa et al. 
2001, Melillo et al. 2001a, Melillo et al. 2001b, Grimm et al. 2000, Murakami et 
al. 2002, Pelicci et al. 2002, Andreozzi et al. 2003, Crowder et al. 2004). Upon 
ligand stimulation, at least two distinct protein complexes assemble on 
phosphorylated Tyr1062 via Shc, one leading to activation of the Ras/ERK 
pathway through recruitment of Grb2/Sos and another to the PI3K/Akt pathway 
through recruitment of Grb2/GAB1/2. This latter complex can also assemble 
directly onto phosphorylated Tyr1096, offering an alternative route to PI3K 
activation by GDNF (Besset et al. 2000, Hayashi et al. 2000). The Ras/ERK 
and PI3K pathways via Tyr1062 are important for activation of CREB and 
NFκB transcription factors, respectively (Hayashi et al. 2000). Big mitogen-
activated protein kinase 1 (BMK1) is also activated via Tyr1062 (Hayashi et al. 
2001).  
The signalling via Tyr1062 plays a crucial role in the migration and/or 
proliferation of enteric nervous system progenitors and it is required for 
ureteric bud branching at later stages of nephrogenesis (Jijiwa et al. 2004). The 
binding of Shc, ShcC, FRS2, IRS1/2, and Dok proteins to Tyr1062 is 
dependent on phosphorylation of this residue and it is mediated by PTB 
phosphotyrosine binding domain. In contrast, the binding to Tyr1062 of 
Enigma, a member of the PDZ-LIM family, is phosphorylation-independent. 
Furthermore, Enigma binds specifically RET9, since short isoform-specific 
amino acid residues +2 to +4 to Tyr1062 are required for interaction with 
Enigma (Borrello et al. 2002). After the elevation of cyclic AMP (cAMP) 
levels, Ser696 is also phosphorylated. Protein kinase A (PKA)-dependent 
Ser696 phosphorylation is important for GDNF/RET-induced Rac activation 
and lamellipodia formation (Fukuda et al. 2002), indicating that cytoskeletal 
rearrangement by the activation of RET is controlled probably by a cAMP-
dependent mechanism via serine phosphorylation. The role in RET signalling 
of additional tyrosine residues that are phosphorylated upon GFLs binding 
(Tyr687, Tyr826 and Tyr1029) remains unclear.  
Tyr752 and Tyr928 in the constitutive active RET serve as docking sites 
for STAT3 (Schuringa et al. 2001). The phosphoinositide-dependent kinase 1 
(PDK1) and STAT1 are phosphorylated and activated by oncogenic RET/PTC 
(Kim et al. 2003, Hwang et al. 2004). RET activates several pathways typical 
of Receptor Tyrosine Kinase signalling. These include the Ras/RAF pathway, 
which leads to activation of the mitogen activated protein kinases ERK1 and 
ERK2 (Santoro et al.1994, van Weering et al.1995, Worby et al.1996, Trupp et 
al.1999), phosphatidylinositol 3-kinase (PI3K), resulting in activation of the 
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serine-threonine kinase Akt and cell survival (van Weering and Bos 1997, 
Trupp et al.1999, Segouffin-Cariou and Billaud 2000, Maeda et al. 2004), Jun 
NH2-terminal protein kinase (JNK) (Chiariello et al. 1998), p38MAPK 
(Kurokawa et al. 2003), ERK5 (Hayashi et al. 2001) and PLC-γ(Borrello et al. 
1996).  
The Ras/MAP kinase pathway appears to contribute to neuronal 
survival and neurite outgrowth in the nervous system (Creedon et al. 1997, van 
Weering et al. 1997) and to ureteric branching during nephrogenesis (Fisher et 
al. 2001). PI3K signalling (possibly independent of its downstream substrate, 
the Ser/Thr-kinase Akt) is required for GDNF-induced formation of large 
lamellipodia, which are implicated in neuritogenesis (van Weering et al.1997, 
van Weering et al.1998, Maeda et al. 2004) and differentiation of cultured 
dopamine neurons (Pong et al. 1998). RET can activate the JNK pathway via 
Rho/Rac related small GTPases, such as Cdc42 (Chiariello et al. 1998). Both 
PI3K/Akt and JNK pathways are key regulators of neurotrophin-dependent 
neuronal survival (reviewed by Kaplan and Miller, 2000), suggesting that they 
may also play roles in mediating the trophic effects generated by RET 
signalling. Abrogation of PLC-γ- dependent signalling blocks the oncogenic 
activity of RET (Borrello et al. 1996). The PLC-γ pathway regulates the 
intracellular level of Ca2+ ions by increasing the level of inositol (1,4,5)-
trisphosphate. Changes in intracellular free Ca2+ concentration are important in 
the action of neurotrophic factors by activating many signal transduction 
cascades. A brief illustration of RET mediated signaling is shown in Figure 5. 
 
 
Figure 5 
 
Figure 5. Schematic illustration of the intracellular signaling transducers interacting with 
activated RET. Enigma binding to Tyr 1062 is phosphorylation independent.  
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1.2.3 RET in human malignancies 
The clinical relevance of RET in human diseases was first recognized in 
papillary thyroid carcinomas (PTC), which derive from the follicular cells, 
followed by Medullary Thyroid Carcinomas (MTC) deriving from 
parafollicular C-cells of thyroid and then in Hirschprung’s disease. The later is 
a result of loss-of-function mutations in the RET gene, while the formers (PTC 
and MTC) results from a gain-of-function in the RET gene (Mulligan et al. 
1993). 
 
 
1.2.3.1 RET/PTC and papillary thyroid carcinomas 
Papillary thyroid carcinomas are frequently associated with specific 
rearrangements affecting the RET gene (Pierotti et al. 1996).  These 
rearrangements lead to the fusion of the RET TK – encoding domain to the 5’- 
terminal regions of heterologous genes, generating chimeric oncogenes 
designated RET/PTC. This results in ligand independent dimerization and 
constitutive activation of kinase function. Moreover, RET/PTC does not have a 
transmembrane domain, and thus is not an integral membrane protein. To date, 
at least 15 different variants of RET/PTC composed of an upstream portion of 
10 various genes fused to the RET kinase domain have been described (Santoro 
et al. 2002) (Figure 6). 
 
Figure 6 
 
 
 
Figure 6. Schematic representation of the RET/PTC oncogenes.  
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The most frequent are RET/PTC1 and RET/PTC3, that arise due to paracentric 
inversion of human chromosome 10. Other less common variants, usually 
forming as a result of inter-chromosomal translocations are unique or occur in 
an extremely limited number of cases. High prevalence of RET gene 
rearrangements are seen in post Chernobyl tumors with a significant 
predominance of RFG/RET (RET/PTC3), over H4/RET (RET/PTC1) 
rearrangements (Thomas et al. 1999, Hartmut et al. 2000). Recently a novel 
variant of rearranged RET was found in an externally irradiated patient who 
developed PTC, because the upstream portion of chimeric gene was composed 
of the first 3 exons of rfp (RET finger protein) gene, designated as ΔRFP/RET 
(Saenko et al. 2003). RET/PTC rearrangements activate the transforming 
potential of RET by multiple mechanisms (Santoro et al. 2002). First, by 
substituting its transcriptional promoter with those of the fusion partners, they 
allow the expression of RET in the epithelial follicular thyroid cells, where it is 
normally transcriptionally silent. Secondly, the rearranged constitutively active 
chimeric oncoproteins are distributed in the cytosolic compartment of the cell. 
More importantly, the RET/PTC kinases form dimers due to the presence of 
protein-protein interaction motifs in RET fusion partners.  
 
 
1.2.3.2 Point mutations in RET 
Germline RET mutations are responsible for development of MEN2A, MEN2B 
and FMTC (Mulligan et al. 1993, Carlson et al. 1994, Eng 1999). MEN2A and 
MEN2B are autosomal dominant cancer syndromes characterized by 
pheochromocytoma and medullary thyroid carcinoma (MTC), a tumor of 
thyroid parafollicular C cells. Familial medullary thyroid cancer (FMTC) is an 
inherited disorder that leads to the development of medullary thyroid cancer. In 
general, patients with FMTC tend to develop tumors at an older age than 
patients with MEN2A and MEN2B. They also tend to have a more favorable 
prognosis. The affected members in MEN2A families develop MTC (100% of 
cases), pheochromocytoma (50% of cases), and parathyroid hyperplasia (15 -
30%). MEN2B patients are known to develop MTC (100% of cases), with an 
aggressive clinical course and early onset and pheochromocytoma (50% of 
cases). MEN2B patients also show a more complex phenotype including 
ganglioneuromatosis of the gastrointestinal tract and mucosa, medullated 
corneal nerves, and marfonoid habitus.  
MEN2A and FMTC mutations have been identified in one of the 
cysteine residues in the RET extra-cellular domain (Eng 1999). Approximately 
90% of MEN2A mutations affect codon 634 and the most frequent substitution 
is a cysteine to arginine change (C634R) (Ichihara et al. 2004). In addition, a 9 
or 12 base pair duplication in exon 11 and a 9 base pair duplication in exon 8 
that create an additional cysteine residue were reported in two MEN 2A 
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families and one FMTC family, respectively (Hoppner & Ritter 1997, Hoppner 
et al. 1998, Pigny 1999). 
FMTC mutations are similar to those causing MEN2A, but are more 
homogeneously distributed among cysteines 609, 618, and 620. Mutations of 
residues 768, 790, 791 (exon 13), 804, 844 (exon 14), or 891 (exon 15) of the 
RET tyrosine kinase domain have also been found in FMTC patients. Recently, 
a pheochromocytoma was described with a codon 891 mutation, indicating that 
patients with this mutation have a predisposition for MEN2A (Jimenez et al. 
2004). Moreover, a point mutation at codon 533 (Da Silva et al. 2004) in exon 
8, resulting in an additional cysteine, or mutations at codons 804 and 778 on 
the same RET allele, associated with both FMTC and prominent corneal nerves 
(Kasprzak et al. 2001), have been described. Additional novel mutations have 
been reported. For instance in the frame of this study (manuscript C) we could 
characterize a novel heterozygous RET germline mutation (N777S) that was 
associated to low penetrant FMTC. 
Two missense point mutations at codon 918 (exon 16) or codon 883 
(exon 15) were associated with MEN2B (Eng 1999). Methionine at codon 918 
and alanine at codon 883 were replaced with threonine and phenylalanine 
(designated M918T and A883F), respectively. The M918T mutation modifies 
the structure of kinase, thereby switching on the enzymatic function and 
altering the substrate specificity of RET/MEN2B (Iwashita et al. 1996, Iwashita 
et al. 1999). More than 95% of MEN2B patients carry the M918T mutation and 
in fewer than 4% cases the A883F mutation was found (Smith et al. 1997). 
Double germline mutations at codon 804 and 806 were also reported in a 
Japanese patient with MEN 2B phenotype (Miyauchi et al 1999). 
 All these point mutations of RET have a “gain of function” effect. 
Constitutive dimerisation is the molecular mechanism of the activation of RET 
molecules carrying mutations affecting extracellular cysteines (Santoro et al. 
1995, Borrello et al. 1995, Asai et al. 1995). Although the three-dimensional 
structure of the RET extracellular domain is still unknown, the cysteine 
residues likely form intramolecular disulfide bonds in the wild-type receptor, 
and the mutation results in an unpaired cysteine, which forms an activating 
intermolecular bridge. In addition, mutations at codons 609, 618, and 620 
markedly decrease the cell surface expression of RET (Carlomagno et al. 1997, 
Ito et al. 1997, Chappuis-Flament et al. 1998). Low maturation efficiencies and 
different intensities in the induction of the dimerisation may explain the 
phenotypes caused by mutations of the different cysteines. Indeed, kinase and 
oncogenic activities of RET mutant proteins associated with FMTC are lower 
than those of the classic MEN2A proteins. No data are yet available on the 
mechanisms of activation of FMTC mutations occurring in RET tyrosine 
kinase domain. RET carrying mutations at codons 768, 804, or 891 display 
lower transforming capacity compared to RET with substitutions at codons 
634, 918, or 883 that are associated with MEN2A and MEN2B, respectively 
(Pasini et al.1997, Iwashita et al. 1999). The MEN2B mutations cause 
constitutive activation of the RET transforming potential. However, in addition 
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to “quantitative” changes of the basal kinase activity, the most frequent MEN 
2B mutation (Met 918Thr) has been proposed to affect also the “quality” of 
RET-generated intracellular signals (Santoro et al. 1995). The residue 
corresponding to methionine 918 is highly conserved in all receptor tyrosine 
kinases, whereas cytoplasmic protein tyrosine kinases show a threonine in that 
position (Marengere et al. 1994). This residue is predicted to alter the substrate 
selection, as it maps in the pocket of the kinase involved in substrate binding 
(Songyang et al. 1995, Pandit et al. 1996). The change in substrate specificity 
can affect RET-mediated phosphorylation of intracellular proteins as well as 
the pattern of RET autophosphorylation sites. Both possibilities have been 
experimentally proven. The pattern of phosphorylated intracellular proteins 
differs in RET/MEN2B and RET/MEN2A expressing cells (Santoro et al. 
1995, Murakami et al. 1999, Salvatore et al. 2001). Moreover, phosphopeptide 
mapping and antibodies specific to RET autophosphorylation sites have shown 
that RET/MEN2B autophosphorylation sites differ from those of wild-type 
RET and of RET/MEN2A (Santoro et al. 1995, Liu et al. 1996, Salvatore et al. 
2001). 
 There are different molecular mechanisms by which the M918T mutation 
alters RET function. This mutation leads to ligand-independent activation of 
the kinase without causing a constitutive dimerisation of the RET molecules. 
On the other hand, the M918T substitution modifies RET substrate specificity. 
In addition, MEN2B kinase activity can be further enhanced by the ligand 
(Carlomagno et al. 1997) and this probably results a stimulation that is stronger 
than that caused by the MEN2A mutation. The combinations of these 
mechanisms may thus explain why MEN2B is the most aggressive form of 
MEN2. It is not known how the A883F affects RET function. However, residue 
883 is located in subdomain of RET that defines substrate preference (Smith et 
al. 1997), suggesting that the alteration of substrate specificity may be a 
common factor that underlies the pathogenesis of MEN2B. A mouse model of 
MEN2B where the corresponding mutation was introduced to the RET gene 
demonstrated that heterozygous mutant mice displayed several features of the  
human disease, including C cell hyperplasia and chromaffin cell hyperplasia 
progressing to pheochromocytoma, while homozygotes displayed more severe  
thyroid and adrenal disease, ganglioneuromas of the adrenal medulla and  
enlargement of the associated sympathetic ganglia and male infertility (Smith-  
Hicks et al. 2000).  
 Recent studies have reported the presence of papillary thyroid carcinoma 
in patients affected by FMTC carrying germline point mutations in RET at 
codons 603 (Rey et al. 2001), 634 (Melillo et al. 2004), 777 (manuscript C) 
790, 791, 804 (Feldman et al. 2000, Brauckhoff et al. 2002, Papi et al. 2003), 
and 918 (Orlandi et al. 2001). Furthermore, one particular transgenic mice line 
bearing the RET (C634R) allele under the control of the calcitonin promoter 
developed both MTC and PTC (Reynolds et al. 2001). Thus, under specific 
circumstances, point mutations in RET can drive the generation of PTC. The 
low mitogenic activity of RET point mutants compared to RET/PTC and the 
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presence of the intracellular juxtamembrane domain that exerts negative effects 
on mitogenic signalling of RET oncoproteins provide a possible explanation for 
the rare association of MTC with PTC (Melillo et al. 2004). The possibility that 
a small number of MTCs arise from a common stem cell (possibly the 
ultimobranchial body) that may give rise to both MTC and PTC has also been 
suggested (Kovacs et al. 1994). 
While gain-of-function mutations associated to RET cause neoplastic 
diseases (associated with MTC and PTC), loss-of-function mutations of RET 
are known to cause a non-neoplastic disease – Hirschsprung disease or 
congenital megacolon (HSCR, Online Mendelian Inheritance in Men OMIM 
142623). This is a developmental disorder of the autonomic innervation of the 
gut regarded as the consequence of premature arrest of the craniocaudal 
migration of neural crest-derived enteric neurons towards the anal end of the 
rectum, which occurs between weeks 5 and 12 of gestation. This causes the 
absence of autonomic ganglion cells within intestinal parasympathetic 
Meissner's and Auerbach's plexuses and, as a consequence, a functional 
obstruction resulting in megacolon (Okamoto and Ueda 1967). A linkage 
analysis has demonstrated that one HSCR susceptibility locus is located on 
chromosome 10q11.2, where the RET gene was mapped (Angrist et al. 1993, 
Lyonnet et al. 1993). Indeed, partial deletions of chromosome 10, which 
encompass the RET locus, were detected in some HSCR patients (Martucciello 
et al.1992, Luo et al.1993). There is evidence that 'loss of function' of RET is 
associated with HSCR. The targeted disruption of RET causes a lack of enteric 
ganglion cells of the myenteric and submucosal plexuses in homozygous mice 
(Schuchardt et al. 1994). RET mutations are spread throughout the coding 
sequence and include deletion, insertion, frameshift, nonsense, and missense 
mutations (Eng and Mulligan 1997, Parisi and Kapur 2000, Iwashita et al. 
2001, Carlomagno et al.1996). 
 
 
1.3 RET as a potential target for molecular cancer therapy 
As reviewed by de Groot et al (2006) the current recommended treatment for 
PTC is total thyroidectomy followed by adjuvant 131I therapy. Alternative 
treatment options have limited effect. In general, this treatment strategy is safe. 
However, in around 20% of patients, treatment is unsuccessful, and patients 
with persistent disease have a median life expectancy compared with the 
general population of only 60%. In MTC and pheochromocytoma, surgery is 
the only treatment option with curative intent. Once MTC and, in rare cases, 
MEN2-associated malignant pheochromocytoma has metastasized, there are no 
therapeutic options.  
The term ‘targeted therapy’ refers to the new generation of cancer drugs 
designed to interfere with a specific molecular target (typically a protein) that is 
believed to have critical role in tumor growth or progression. The identification 
of appropriate targets is based on a detailed understanding of the molecular 
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changes underlying cancer. The demonstration that the expression of oncogenic 
RET variants alone is sufficient to transform NIH3T3 fibroblasts, indicates that 
RET is a functional oncogene (Santoro et al. 1995). The causative role played 
by RET germline mutations in familial MTC, the presence of RET alterations 
in early phases of PTC, and the ability of RET oncogenes to initiate tumor 
formation in tissue specific transgenic animals support this concept (Fagin 
2004). 
Recently, the expression of dominant–negative RET mutants has been 
used to block MTC cell line growth in vitro (Drosten et al. 2002). Adenovirus 
mediated transduction of dominant-negative RET in to human MEN type 2 cell 
lines (TT), resulted in the induction of apoptosis (Drosten et al. 2003). The 
disadvantages of this approach are the limited transduction efficiencies and the 
drawbacks of gene therapy. However these results indicate usefulness of RET 
as a target for therapy. The alternative approach for targeting RET is through 
monoclonal antibodies against RET. Monoclonal antibodies recognizing RET 
mature glycosylated and immature forms have been generated (Salvatore et al. 
2002). However the disadvantages of monoclonal antibody approach include 
humanization, cost of production and hypersensitivity reactions. Recently 
nuclease-resistant aptamers that recognize and inhibit RET have been 
developed (Reviewed by de Groot et al. 2006). Promising pre-clinical and 
clinical results with small molecular weight inhibitors of other kinases in the 
recent years have emphasized the role of RET as a potential target for these 
compounds. 
 
 
1.3.1 Small molecule kinase inhibitors    
The clinical success of the small molecule kinase inhibitor STI571 or imatinib 
mesylate (Gleevec), targeting BCR/ABL in chronic myeloid leukaemia (CML), 
FIP1L1-PDGFRα associated Idiopathic Hypereosinophilic Syndrome (HES), 
KIT or PDGFR-α associated Gastrointestinal stromal tumours (GIST), and 
dermatofibroma protuberans, giant cell fibroblastoma, and glioblastoma 
overexpressing PDGF (Buchdunger et al, 2000, Sjoblom et al, 2001) has 
demonstrated the power of small molecular weight kinase inhibitors (Druker et 
al. 2001, Demetri et al. 2002). STI571 is now available in the market as an 
approved drug for the treatment of BCR/ABL+ CML (Capdeville et al. 2002). 
Till date, an overwhelming number of natural and synthetic small molecules 
inhibitors of tyrosine kinases have been described. Figure 7 illustrates selected 
tyrosine kinase inhibitors presently in clinical trials. 
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Figure 7 
 
 
Figure 7. Chemical structures of various small molecule kinase inhibitors, currently under 
phase I/II clinical trials.  
 
 
Small molecular weight inhibitors can be broadly categorized into natural 
products and related derivatives (quercetin, genistein, staurosporine, 
erbastatins, clavilactones); quinazolines, pyridopyrimidines, and related 
compounds (e.g., ZD1839); phenylamino-pyrimidines, (e.g., STI71); 
tryphostins and analogues (e.g., SU1498, SU101, SU0020); indoles and 
oxindoles (e.g., SU5416, SU6668, SU5402) (Al-obeidi & Lam 2000).  
ZD1839-(Iressa)[4-(3-chloro-4-fluoroanilino)-7-methoxy-6-(3-
morpholinoproxy)quinazoline] is an EGFR kinase inhibitor [IC50 (Half 
Maximal Inhibitor Concentration) value between 23 and 79 nM], and has 
proved its efficacy in the treatment of non-small cell lung carcinoma and 
glioblastoma (Penne et al. 2005). SU6668, SU5416 (semaxanib), ZD6474 are 
shown as potential KDR tyrosine kinase inhibitors and their efficacy has  been 
widely tested as angiogenesis blockers (Laird et al. 2000, Fong et al. 1999, 
Wedge et al. 2002). Most small molecules in the clinical development bind in 
the vicinity of the ATP-binding site of their target kinases, using a part of their 
scaffold to mimic the binding of the adenine moiety of ATP. Such ATP mimics 
are competitive inhibitors of the substrate-binding sites within the catalytic 
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domain (Laird & Cherrington 2003, Fry 2003). Although ATP-binding site is 
highly conserved among tyrosine kinases, minor differences in kinase domain 
architecture have allowed development of highly selective inhibitors (Levitzki 
2002). 
 
 
1.3.2 Discovery of RET inhibitors 
Several recent studies have obtained promising results using available tyrosine 
kinase inhibitors against RET. A dose dependent inhibition of RET 
autophosphorylation after the exposure of MTC-derived TT cells to STI571 
have been observed. This effect was accompanied by an inhibition of cell 
proliferation, these results indicate that STI571 at high doses possesses activity 
against the RET receptor tyrosine kinase (Cohen et al. 2002). The average in 
vitro IC50 of STI571 for RET is 37 µM +/- 4 µΜ. The concentrations of 
STI571 required to significantly inhibit RET and to inhibit TT cell proliferation 
are not clinically achievable. Hence, STI571 is not likely to be an effective 
treatment for MTC (Skinner et al. 2003).  
 The pyrazolo-pyrimidine PP1 inhibited RET-derived oncoproteins with 
an IC50 of 80 nM. Furthermore, RET/PTC3-transformed cells treated with 5 
µM of PP1 lost proliferative autonomy and showed morphological reversion. 
PP1 prevented the growth of two human papillary thyroid carcinoma cell lines 
that carry spontaneous RET/PTC1 rearrangements and blocked anchorage-
independent growth and tumorigenicity in nude mice of NIH3T3 fibroblasts 
transformed by RET/PTC3 oncogene. These findings suggest targeting RET 
oncogenes with PP1 or related compounds as a novel treatment strategy for 
RET-associated neoplasms (Carlomagno et al. 2002b). PP2, another 
pyrazolopyrimidine, which is structurally very homologue to PP1, blocks the 
enzymatic activity of the isolated RET kinase and RET/PTC1 oncoprotein with 
an IC50 in the nanomolar range. PP2 blocked in vivo phosphorylation and 
signaling of the RET/PTC1 oncoprotein and prevented serum-independent 
growth of RET/PTC1-transformed NIH3T3 fibroblasts and TPC1 and FB2, two 
papillary thyroid carcinoma cell lines (that carry spontaneous RET/PTC1 
rearrangements) (Carlomagno et al. 2003). In two other studies it is 
demonstrated the 2-indolinone derivative RPI-1 to inhibit the transforming 
ability of the RET/PTC1 oncogene (Lanzi et al. 2000 & 2003). 
It has also been shown that the indolocarbazole derivatives, CEP-701 
and CEP-751, inhibit RET in MTC cells. These compounds effectively inhibit 
RET phosphorylation in a dose-dependent manner at concentrations <100 nM 
in 0.5% serum and at somewhat higher concentrations in the presence of 16% 
serum. They also blocked the growth of these MTC cells in culture. CEP-751 
and its prodrug, CEP-2563, also inhibited tumor growth in MTC cell 
xenografts (Strock et al. 2003). Later the same group has shown that Irinotecan 
treatment can be highly effective in a preclinical model of human MTC, 
resulting in complete remission in 100% of the xenografts treated. The duration 
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of remission was further enhanced by combination with the kinase inhibitor, 
CEP-751. These results suggest that irinotecan, alone or in combination, may 
be useful for the treatment of MTC (Strock et al. 2006). 
The anilinoquinazoline ZD6474 is a potent inhibitor of vascular 
endothelial growth factor (VEGF) receptor-2 (flk-1 or KDR) following oral 
administration, and is currently being evaluated in a phase-II clinical trial 
against non-small-cell lung carcinoma (NSCLC) and breast cancer (Wedge et 
al. 2002). In a recent study it has been shown that ZD6474, blocks the 
enzymatic activity of RET-derived oncoproteins at a IC50 of 100 nM. ZD6474 
blocked in vivo phosphorylation and signaling of the RET/PTC3 and 
RET/MEN2B oncoproteins and of an epidermal growth factor (EGF)-
receptor/RET chimeric receptor. RET/PTC3-transformed cells, treated with 
ZD6474 lost proliferative autonomy and showed morphological reversion. 
ZD6474 prevented the growth of two human PTC cell lines that carry 
spontaneous RET/PTC1 rearrangements. It blocked anchorage- independent 
growth of RET/PTC3-transformed NIH3T3 fibroblasts and the formation of 
tumors after injection of NIH-RET/PTC3 cells into nude mice (Carlomagno et 
al. 2002a). Vidal et al. (2005) developed a Drosophila model for MEN2A and 
MEN2B diseases by targeting oncogenic forms of RET to the developing 
Drosophila eye. They showed that, when fed orally, ZD6474 suppressed RET-
mediated phenotypes within the context of this in vivo model. ZD6474 showed 
high efficacy and very low toxicity. Currently a two stage, phase II clinical 
study sponsored by AstraZeneca is under progress to evaluate the efficacy and 
tolerability of ZD6474 in patients with locally advanced or metastatic 
hereditary medullary thyroid carcinoma (ClinicalTrials.gov Identifier: 
NCT00098345). 
 
 
1.4 Resistance to selective kinase inhibitors 
Although targeted therapy is yielding promising results in the treatment of 
specific cancers, drug resistance poses a major problem. Resistance to kinase 
inhibitors may occur due to mutations in the kinase domain that activate the 
kinase and block the inhibitor binding. Imatinib induces complete remission in 
virtually all patients in the chronic phase of CML (Kantarjian et al. 2002). 
When treated during the more aggressive stage of blast crisis, patients 
ultimately develop drug-resistance diseases (Druker et al. 2001, Sawyers et al. 
2002). The majority of relapsed patients harbor mutations within the BCR/ABL 
kinase domain (Shah et al. 2002). A high frequency of mutations clustered 
within the ATP-binding region of BCR/ABL has been registered in resistant 
patients (Branford et al. 2002). Some mutations as T315I, Y253H, and F317L, 
have a predicted role in abrogating imatinib binding to BCR/ABL, by blocking 
the ATP binding pocket for the entry of imatinib, whereas some others E255K, 
G250E, and M351T do not. Recently it has been shown that, substitution at 
T670I, affecting the ATP/imatinib pocket of KIT, makes it insensitive to the 
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drug. Interestingly, this substitution corresponds to the ABL/T315I mutation 
already reported in imatinib resistant CML patients, (Tamborini et al. 2004). 
Furthermore a patient with HES developed a T674I imatinib resistant mutation 
in the kinase domain of FIP1L1-PDGFRα while on therapy (Cools et al. 2003). 
Interestingly the T674I mutation in FIP1L1-PDGFRα also corresponds to the 
drug resistant mutation T315I in BCR/ABL. Lung adenocarcinomas from 
patients who respond to the tyrosine kinase inhibitor Gefitinib (Iressa) usually 
harbor somatic gain-of-function mutations in exons encoding the kinase 
domain of the EGFR. In two out of five patients that acquired resistance to 
Gefitinib, the progressing tumors harbored, in addition to the primary drug-
sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to 
substitution of methionine for threonine at position 790 (T790M) in the kinase 
domain (Pao et al. 2002). T315 in ABL occupies the same position as T670 in 
KIT, T674 in PDGFRα and T790 in EGFR. 
As previously described mastocytosis, which is a heterogeneous clinical 
entity, might, in some patients, result from mutations in KIT (Nagata et al. 
1995). Some of the mutations found in patients with mastocytosis are 
Gly560Val, Asp816Val, Asp816Tyr, and Asp820Gly. All mutations with the 
exception of Gly560Val cluster to KIT exon 17. It is found that the Asp816Val 
substitution confers resistance to the KIT-inhibitory drug imatinib (Ma et al. 
2002). Accordingly, the activating mutations in the activation loops of other 
kinases like FLT3, KIT, and PDGFR (one such example is D842V mutation in 
PDGFRα and D816V mutation in KIT) confer resistance to imatinib, but are 
sensitive to a number of other inhibitors (Heinrich et al. 2003, Corbin et al. 
2005, Debiec-Rychter et al. 2005). These mutations can also be implicated in 
the development of secondary resistance as they are followed longer time 
periods. 
As previously described mutations of the target kinase can be crucial in 
acquired resistance mechanism. Imatinib as well as most other small molecule 
kinase inhibitors are ATP competitors and the interference with kinase activity 
is strictly dependent on ATP availability (Capdeville et al.2002). Both ATP and 
the inhibitors fit within the ATP-binding pocket of the kinase domain, and their 
binding is stabilized by interactions with specific amino acids in the binding 
site (Schindler et al. 2000). As a consequence, point mutations changing key 
amino acids at the ATP binding pocket, can result in the resistance of the 
kinase (Gorre et al. 2001). In addition the mutations can also alter the 
confirmation of the kinase enabling resistance to inhibitors. One such example 
comes from imatinib-BCR/ABL interaction. Imatinib can only bind to the 
inactive conformation of BCR/ABL, corresponding to the form with closed, 
unphosphorylated activation loop (Schindler et al. 2000). As a result, point 
mutations that destabilize the inactive conformation, either by mutation of the 
activation loop or mutation of SH2/SH3 contact site, have a negative affect on 
imatinib binding (Courtneidge 2003). To obtain a more comprehensive survey 
of the amino acid substitutions that confer imatinib resistance, Azam et al. 
(2003) performed an in vitro screen of randomly mutagenized BCR/ABL and 
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recovered all of the major mutations previously identified in patients and 
numerous others that illuminate novel mechanisms of acquired drug resistance. 
A second mechanism of resistance is gene amplification of the drug 
target. High-level amplification of BCR/ABL was recognized in a fraction of 
resistant cases that did not harbor additional resistant mutations (Gorre et al. 
2001). It has also been described as a mechanism of resistance in GIST patients 
with oncogenic KIT mutations (Debiec-Rychter et al. 2005).  
As a third mechanism of drug resistance, it has been shown that the 
resistance of non-small-cell lung carcinoma cells to Gefitinib (ZD 1839) is 
attributable to EGFR-independent constitutive Akt activation caused by loss of 
PTEN function in these cells. Much of the effects of PTEN loss caused 
overactive PI3K/Akt pathway signalling (She et al. 2003). 
Recently a fourth mechanism of resistance has been identified in a study 
of the development of resistance during imatinib treatment of GIST patients 
with primary KIT mutations (Debiec-Rychter et al. 2005). The growth 
dependency of the cancer cell is shifted to a new mutated tyrosine kinase which 
is not targettable by the compound. In this case sequence analysis of the 
PDGFRα gene in the cancer cells of a patient with GIST upon treatment with 
imatinib, revealed a new mutation at the time of relapse, encoding a change of 
Asp at position 842 to Val (D842V). The D842V mutation was characterized as 
an activating mutation that also confers resistance to imatinib (Debiec-Rychter 
et al. 2005). 
Finally, lower intracellular concentrations of the tyrosine kinase 
inhibitor can hinder its inhibitory efficiency. Several factors like water 
solubility, ionization, binding to plasma proteins, influx rate in to the cell and 
efflux rate out of the cell are important in determining the bioavailability of the 
compound. It has been shown that imatinib can bind to the α1 acid 
glycoprotein, lowering its free plasma concentration and affecting its 
intracellular levels (Gambacorti-Passerini et al. 2003). In another study, it has 
been demonstrated that inappropriate expression of the multidrug resistance 
(MDR1) gene encoding the P-glycoprotein (Pgp) can confer resistance to 
different chemotherapeutic drugs (Mahon et al. 2003). 
In line with the large number of small molecule kinase inhibitors under 
development, protein kinases are expected to become the major drug targets of 
the 21-century. However as a consequence of above mentioned limitations, the 
success in the strategies to override resistance in this setting may greatly 
depend on the fast and accurate identification of the resistance mutation and the 
selection of the correct inhibitor to overcome the resistance (Cools et al. 2005).  
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2.  AIMS OF THE STUDY 
This study was initiated based on previous studies that showed the RET 
receptor tyrosine kinase as a key target in the treatment of RET dependent 
medullary thyroid carcinoma (MTC). Several small molecular weight kinase 
inhibitors were shown to inhibit constitutively active RET tyrosine kinase. 
Recently a Phase II clinical study to evaluate the efficacy and tolerability of 
ZD6474 in patients with advanced or metastatic hereditary MTC has been 
launched by AstraZeneca. However, resistant mutations can be found in 
patients proir to treatment or can develop during the course of treatment. 
Therefore: 
 The first aim of this study was to identify the residues that can mediate 
drug resistance of the RET tyrosine kinase.  
 The second aim was to identify a small molecular weight kinase inhibitor 
that can overcome resistance.  
 Finally, we verified whether the same kinase inhibitor could be also used 
to target mutants of other kinases that, similarly to RET, are resistant to 
kinase inhibitors 
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3.  MATERIALS AND METHODS 
 
3.1 Compounds 
ZD6474 (zactima™) [N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-
methylpiperidin-4-yl)methoxy]quinazolin-4-amine] was kindly provided by 
Astra Zeneca (Pharmaceuticals, Macclesfield, UK).  
 
Figure 8: Chemical structure of ZD6474 
 
 
 
 
 
PP1, 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]-pyrimidine, was 
purchased from Alexis (San Diego, CA). 
 
Figure 9: Chemical structure of PP1 
 
 
 
BAY 43-9006 (Sorafenib™), N-(3-trifluoromethyl-4-chlorophenyl)-N’-(4-[2-
methylcarbomoyl pyridin-4-yl]oxyphenyl)urea, was provided by Bayer 
healthcare pharmaceuticals (West haven, CT).  
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Figure 10: Chemical structure of BAY 43-9006  
 
 
 
 
For in vitro experiments 50 mM stock solutions of ZD6474, PP1, and BAY 43-
9006 were prepared in 100% dimethylsulfoxide (DMSO) and diluted with 
culture media or kinase buffer before use. Culture media or kinase buffer 
containing an equivalent DMSO concentration served as vehicle controls. For 
in vivo experiments, BAY 43-9006 was dissolved in Cremophor EL-ethanol 
(50:50 sigma Cremophor EL-95% ethyl alchohol) (Sigma chemicals Co., MO) 
at fourfold (4X) the highest dose, foil wrapped, and stored at room temperature. 
The 4X stock solution was prepared fresh every 3 days. The final dosing 
solution was prepared on the day of use by diluting the stock solution to 1 X 
with water. 
 
 
3.2 DNA constructs 
Mutations C634R, M918T, A883F, E768D, L790F, Y791F, V804L, V804M 
and S891A were introduced in the full length cDNA of human RET9, encoding 
the short isoform of RET protein, cloned in the pBABE expression vector 
(Pasini et al. 1997). RET/C634R was introduced into pcDNA3.1A- (Myc-His) 
mammalian expression vector (Invitrogen, Groningen, The Netherlands) fused 
in frame at the C terminus with a myc epitope or a His tag (Melillo et al. 2001). 
The mutation V804M was introduced in pcDNA3.1A- /RETC634R construct to 
generate pcDNA3.1A- /RETC634R–V804M by site directed mutagenesis using 
the primers 5’-GCT CCT CCT CAT C (A*) T GGA GTA CGC CAA ATA -3’ 
and 5’-TAT TTG GCG TAC TCC A (T*) G ATG AGG AGG AGC -3’. The 
mutation V804G was introduced in pcDNA3.1A- /RETC634R construct to 
generate pcDNA3.1A- /RETC634R – V804G by site directed mutagenesis 
using the primers 5’-GCT CCT CCT CAT C G (G*) GGA GTA CGC CAA 
ATA -3’ and 5’-TAT TTG GCG TAC TCC (C*) CG ATG AGG AGG AGC -
3’. The Y806C mutation was inserted in the pBABE RET/C634R construct 
(pBABE RET/C634R-Y806C) by site directed mutagenesis with primers 5’-
CCT CAT CGT GGA GT (G* T*) GC CAA ATA CGG CTC -3’ and 5’-GAG 
CCG TAT TTG GC (A* C*) AC TCC ACG ATG AGG -3’. All the mutations 
were generated using the quick-change site directed mutagenesis kit from 
Stratagene (La Jolla, CA). All these mutations were confirmed by double-
strand DNA sequencing. 
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 The full-length cDNA of wild type human PDGFRβ was amplified 
from human PDGFRβ cDNA kindly provided by C.H. Heldin (Ludwig 
Institute for Cancer Research, Uppsala, Sweden.) with primers containing 5’-
HindIII and 3’-EcoRI restriction sequences (5’- TGA ATT CCG GCT TCC 
GGG TGC GAT GCC AGC T-3’ and 5’- AAG CTT CAG GAA GCT ATC 
CTC TGC TTC CGC -3). The PCR fragment was cloned in pCR-TOPO vector 
(TOPO-TA Cloning kit, Invitrogen) by creating a final fragment with a 
HindIII/EcoRI sites for directional cloning. The product was later, subcloned 
within the HindIII and EcoRI sites in pcDNA3.1. Mutations T681I and D850V 
were introduced in the full length cDNA of human PDGFRβ cloned in 
pcDNA3.1A- by site directed mutagenesis using primers 5’-CCC ATC TAT 
ATC ATC A(T*)T GAG TAC TGC CGC TAC-3’ and 5’-GTA GCG GCA 
GTA CTC (A*)AT GAT GAT ATA GAT GGG -3’ and 5’-GGC CTG GCT 
CGA G(T*)C ATC ATG CGG GAC-3’ and 5’-GTC CCG CAT GAT G(A*)C 
TCG AGC CAG GCC -3’ respectively. These mutations were confirmed with 
double stranded DNA sequencing. 
Murine KIT was cloned in pCMV6 mammalian expression vector 
(kindly provided by C. Sette, Universita’ di Roma) and mutations KIT V559D, 
KIT T670I and KIT D814V were introduced by site directed mutagenesis using 
primers 5’-CAT GTA TGA AGT ACA GTG GAA GG(A*) TGT TGA GGA 
GAT AAA TGG -3’ & 5’-CCA TTT ATC TCC TCA ACA (T*)CC TTC CAC 
TGT ACT TCA TAC ATG -3’,  5’-GCC CAC CCT GGT CAT TA(T*) AGA 
ATA TTG TTG CTA TGG -3’ & 5’-CCA TAG CAA CAA TAT TCT (A*)TA 
ATG ACC AGG GTG GGC-3’ and 5’-GAT TTT GGT CTA GCC AGA 
G(T*)C ATC AAG AAT GAT TCT AAT TAT G -3’ & 5’-CAT AAT TAG 
AAT CAT TCT TGA TG(A*) CTC TGG CTA GAG CAA AAT C -3’ 
respectively. Since the mouse KIT D814V mutation corresponds to the human 
KIT D816V, for the sake of clarity, this mutant is called KIT D816V 
throughout this thesis. These mutations were confirmed with double stranded 
DNA sequencing. CycD1-LUC reporter plasmid was kindly provided by S. J. 
Gutkind (NIH, MD, USA). 
 
 
Table 2: Molecular constructs used in this study 
 
VECTOR Construct 
 
pBABE Expression Vector 
 
 
pcDNA3.1A- 
 
 
pCMV6 
 
RET/C634R, M918T, A883F, E768D, L790F, Y791F, 
V804L, V804M, S891A and RET/C634R- Y806C 
 
RET/C634R, RET/C634R-V804M, PDGFRβ/ T681I 
and PDGFRβ/ D850V 
 
Murine c-KIT / T670I and c-KIT /  D814V 
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3.3 Cell culture 
HEK293 cells were from American type culture collection (ATCC, Manassas, 
Va, USA) and were grown in Dulbecco’s Modified Eagle medium (DMEM) 
supplemented with 10% fetal calf serum (GIBCO, Paisley, PA, USA), 2mM L-
glutamine, and penicillin-streptomycin at 100 units/mL (GIBCO, Paisley, PA, 
USA). All the transient transfections were carried out with the lipofectamine 
reagent according to the manufacturer’s instructions (GIBCO), briefly the cells 
were seeded at a density of 1.5 X 106 /dish, the day before transfection and 
transfected with 5µg of DNA. HEK293 cells transfected with RET/MEN2A 
mutants (RET/C634R-V804M and Y806C) were harvested after 48 hours. The 
cells were serum starved for twenty-four hours and two hours before being 
harvested, they were treated with the varying concentration of the inhibitor. 
 HEK293 cells were transfected with vectors expressing KIT, KIT 
T670I, KIT D816V or PDGFRβ, PDGFRβ T681I and PDGFRβ D850V, with 
the same procedure as described above including “serum-starvation” and 
“short-term treatment” with the inhibitor. KIT wt and KIT T670I transfected 
cells were stimulated with 100 ng/ml SCF (Prepotech, London, UK) for 10 
minutes, whereas PDGFRβ wt and PDGFRβ T681I transfected cells were 
stimulated with 100 ng/ml PDGF BB (Prepotech) for 10 minutes.  
Parental murine NIH3T3 fibroblasts and NIH3T3 cells stably 
transfected with the RET mutants RET/C634R (MEN2A), RET/M918T 
(MEN2B) and wild type RET are described elsewhere (Carlomagno et al. 2002, 
Santoro et al. 1995). Cells were cultured in Dulbecco’s Modified Eagle 
medium (DMEM) supplemented with 5% calf serum (GIBCO, Paisley, PA, 
USA), 2mM L-glutamine, and penicillin-streptomycin at 100 units/mL 
(GIBCO, Paisley, PA, USA). Parental Fischer rat–derived RAT1 fibroblasts 
and RAT1 transformed by RET/C634R, RET/V804L, or RET/V804M are 
described elsewhere (Pasini et al. 1997) and were cultured in DMEM with 10% 
fetal calf serum, 2 mM L-glutamine, and 100 units/mL penicillin-streptomycin 
(GIBCO). All RET constructs used in this study encoded the short isoform of 
the RET protein (RET9) (Santoro et al. 2004). Epidermal growth factor (EGF) 
was purchased from Upstate Ltd (Charlottesville, VA); GDNF was purchased 
from Alomone Labs (Jerusalem, Irael). 
The TPC1 cell line, derived from a human papillary thyroid carcinoma 
harboring the RET/PTC1 rearrangement (Ishijaka et al. 1990), was cultured in 
DMEM with 10% fetal calf serum, 2 mM L -glutamine, and penicillin-
streptomycin at 100 units/mL. The TT cell line, derived from a medullary 
thyroid carcinoma (MTC) harboring the RET/C634W mutation (Carlomagno et 
al. 1995), was cultured in RPMI-1640 with 20% fetal calf serum, 2 mM L-
glutamine, and 100 units/mL penicillin-streptomycin (GIBCO).  
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3.4 Immunoblotting analysis 
Protein lysates were prepared according to standard procedures. Briefly, cells 
transiently expressing RET, KIT and PDGFRβ mutants, mouse fibroblasts and 
human thyroid carcinoma cells or snap-frozen tumor samples were lysed in a 
buffer containing 50 mM HEPES (pH 7.5), 1% (vol/vol) Triton X-100, 150 
mM NaCl, 5 mM EGTA, 50 mM NaF, 20 mM sodium pyrophosphate, 1 mM 
sodium vanadate, 2 mM phenylmethylsulfonyl fluoride, and aprotinin at 1 
µg/mL. Lysates were clarified by centrifugation at 10,000 x g for 15 minutes. 
Equal volumes of lysates containing comparable amounts of proteins, as 
estimated by a modified Bradford assay (Bio-Rad, Munich, Germany) 
(Bradford 1976), were boiled for 5 min in 1X Laemmli sample buffer, and 
resolved on an SDS 10-12% polyacrylamide gel. Proteins were then transferred 
to nitrocellulose membrane (Protran® BA83, Whatman Schleicher & Schuell 
BioScience) at 300mA “over-night”. Blots were incubated with primary 
antibodies for 1 hour at room temperature, followed by three washes in buffer 
(20 mM Tris-HCl at pH 7.5, 150 mM NaCl, and 0.05% Tween 20). The blots 
were then incubated with the goat anti-rabbit secondary antibody (1: 3000) 
coupled to horseradish peroxidase (Bio-Rad, Munich, Germany) for 1 hour at 
room temperature followed by three washes in buffer (20 mM Tris-HCl at pH 
7.5, 150 mM NaCl, and 0.05% Tween 20. Immunocomplexes were detected 
with the enhanced chemiluminescence kit (Amersham Pharmacia Biotech, 
Little Chalfort, UK). Signal intensity was analyzed using a PhosphorImager 
(Typhoon 8600, Amersham Pharmacia Biotech) interfaced with the 
ImageQuant software. Each experiment was performed in triplicate. 
 Anti-RET (1:500) is a rabbit polyclonal antibody raised against the 
tyrosine kinase protein fragment of human RET (Santoro et al. 1995). Anti-
pY1062 and anti-pY905 are affinity-purified polyclonal antibodies raised 
against RET peptides containing phosphorylated Y1062 or Y905 (Salvatore et 
al. 2000, Carlomagno et al. 2003), Anti-KIT (1:1000) and Anti-PDGFRβ 
(1:1000), are rabbit polyclonal antibodies from Santa Cruz Biotechnology 
(Santa Cruz, CA). Anti-phospho PDGFRβ that recognizes phosphorylated 
Y1021 is a goat polyclonal antibody from Santa Cruz Biotechnology (Santa 
Cruz, CA). Anti-phospho KIT (1:3000) that recognizes phosphorylated Y823 is 
a rabbit polyclonal antibody from BioSource (CA, USA). Anti-phospho Shc (1: 
1000), which recognizes phosphorylated Shc at Y317, was a rabbit polyclonal 
antibody from Upstate Biotechnology, Inc. (Lake Placid, NY). Anti-Shc (1: 
1000) was a rabbit polyclonal antibody from Santa Cruz Biotechnology (Santa 
Cruz, CA). Anti-mitogen-activated protein kinase (MAPK) (1:1000) and anti-
phospho MAPK (1:1000), which recognizes p44/42MAPK (ERK1/2) 
phosphorylated at Thr202/Tyr204, were rabbit polyclonal antibodies from Cell 
Signaling (Beverly, MA).   
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3.5 In vitro kinase assay 
Subconfluent cells transfected with different RET constructs were solubilized 
in lysis buffer with phosphatase and protease inhibitors (50 mM HEPES (pH 
7.5), 1% (vol/vol) Triton X-100, 150 mM NaCl, 5 mM EGTA, 50 mM NaF, 20 
mM sodium pyrophosphate, 1 mM sodium vanadate, 2 mM 
phenylmethylsulfonyl fluoride, and aprotinin at 1 µg/mL). For phosphorylation 
of the synthetic substrate, RET mutants were immunoprecipitated with anti-
RET antibodies, immunocomplexes were recovered with protein G sepharose 
beads washed five times with kinase buffer (20mM HEPES at pH-7.5, 150mM 
NaCl, 10% glycerol, 0.1% Triton X-100, 15  mM MnCl2, 15mM Mgcl2) and 
incubated, 20 minutes at room temperature in kinase buffer containing 200 µM 
poly-(L-glutamic acid-L-tyrosine [poly-GT]) (Sigma), 2.5 µCi of [γ-32P]ATP, 
and unlabeled ATP (20 µM) in the presence of the inhibitory compound or 
vehicle. Samples were spotted on Whatman 3MM paper (Springfield Mill, 
UK), and 32P incorporation was measured with a beta counter scintillator 
(Beckman Coulter, Unterschleissheim-Lohhof, Germany). 
 For the in vitro RET autophosphorylation assay, subconfluent NIH3T3 
cells stably transfected with RET/C634R were solubilized in lysis buffer 
without phosphatase inhibitors (sodium fluoride, sodium pyrophosphate, and 
sodium vanadate). Then, 200 µg of proteins were immunoprecipitated with 
anti-RET; immunocomplexes were recovered with protein G–Sepharose beads, 
washed five times with kinase buffer (20 mM HEPES at pH 7.5, 150 mM NaCl, 
10% glycerol, 0.1% Triton X-100, 15 mM MnCl2, and 15 mM MgCl2) and 
incubated 20 minutes at room temperature in kinase buffer containing 2.5 µCi 
of ATP and unlabeled ATP (20 µM) (Carlomagno et al. 2002). Samples were 
separated by 10% SDS-PAGE gel electrophoresis. Gels were dried and exposed 
to film for autoradiography. Signal intensity was analyzed using a 
PhosphorImager (Typhoon 8600) interfaced with the ImageQuant software.  
 HEK293 cells transiently transfected with pcDNA 3.1 vectors encoding 
PDGFRβ T681I and D850V mutants and CMV-6 vectors expressing the KIT 
T670I and KIT D816V mutants were solubilized in lysis buffer with 
phosphotase and protease inhibitors (50 mM HEPES (pH 7.5), 1% (vol/vol) 
Triton X-100, 150 mM NaCl, 5 mM EGTA, 50 mM NaF, 20 mM sodium 
pyrophosphate, 1 mM sodium vanadate, 2 mM phenylmethylsulfonyl fluoride, 
and aprotinin at 1 µg/mL). Appropriate amount of proteins were 
immunoprecipitated with Anti-PDGFR and Anti-KIT antibodies; 
immunocomplexes were captured by protein G-sepharose beads. Kinase assays 
involving PDGFRβ mutants were performed as described by Claesson-Welsh 
et al. (1988). Immunopurified proteins were washed  three times with PDGFR 
wash buffer (20 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic 
acid; pH 7.4), 150mM NaCl, 10% glycerol, 0.2% Triton X-100) and once with 
the same buffer without NaCl and then resuspended in 40 µl of PDGFR kinase 
buffer (20 mM HEPES (pH 7.4), 5 mM MnCl2, 0.2% Triton X-100, 0.1% 
bovine serum albumin). The phosphorylation reaction was then initiated by the 
addition of 1 µM 32P γATP (13 µCi; Amersham) and varying concentrations of 
 37 
inhibitor or vehicle. For autophosphorylation assays with KIT mutants, 
immunocomplexes were washed at 4oC for three times in KIT-wash buffer 
(Phosphate-buffered saline, 0.1% TritonX-100, and 2mM EDTA) and two 
times in Kit-kinase buffer (20mM HEPES, 20mMPIPES at pH7.4 and 10mM 
MnCl2), before resuspension in 25µl of kinase buffer containing, 32P-
radiolabeled ATP and the varying concentrations of the inhibitors (Tatton et al. 
2003). In both cases, reaction samples were incubated for 20 mins at room 
temperature and resoved by 10% SDS–PAGE gel electrophoresis. Gels were 
dried and exposed to film for autoradiography. Signal intensities were analyzed 
using a PhosphorImager (Typhoon 8600) interfaced with the ImageQuant 
software. Kinase activity curves were plotted with the curve-fitting PRISM 
software (GraphPad Software). The inhibitory concentration 50 (IC50) for each 
protein is indicated.  
 
3.6 Growth curve and cell cycle analysis 
NIH3T3 (1×104/dish), RAT1 fibroblasts (1x104/dish), human thyroid 
carcinoma TPC1 (3.5×104/dish) and TT (9×104/dish) cells were seeded in 60-
mm dishes. The cells were maintained with serum concentrations as indicated 
in Table 3. 
 
 
Table 3: Culture conditions for the different cells used in the study 
 
Cells Serum concentration 
NIH3T3 
RAT1 fibroblasts 
TPC1 
TT 
5% Calf Serum 
1% Fetal Calf Serum 
2% Fetal Bovine Serum 
10% Fetal Bovine Serum 
 
The corresponding inhibitor was added, to the medium and changed every 2 
days. Cells were counted every 2 (fibroblasts) or 2–3 (human cell lines) days. 
For flow cytometry analysis, cells were grown to subconfluence in 100-mm 
dishes and then treated with vehicle or 1.0 µM BAY 43-9006 for 24 hours. 
After harvesting, cells were fixed in cold 70% ethanol in phosphate-buffered 
saline. Cells were washed and resuspended in phosphate-buffered saline. 
Propidium iodide (25 µg/mL) was added, and samples were analyzed with a 
FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA) interfaced 
with a Hewlett Packard computer (Palo Alto, CA). Experiments were 
performed three times in duplicate. 
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3.7 Luciferase assay 
HeLa cells (1 × 106/well) were seeded in each well of a 12-well plate. Twenty-
four hours later, cells were transiently transfected with 500 ng of vectors 
expressing RET/C634R, RET/C634R-V804M, RET/C634R-Y806C/E, KIT wt, 
KIT T670I and KIT D816V, and 100 ng of the AP1-Luc vector (Stratagene, 
Garden Grove, CA) containing six AP1 binding sites upstream from the Firefly 
luciferase cDNA, with the Lipofectamine reagent according to the 
manufacturer’s instructions (GIBCO). Twenty-four hours after transfection, 
cells were serum-starved and 100 ng/ml SCF was added to the KIT wt and KIT 
T670I transfected cells. NIH3T3 mouse fibroblasts seeded in 12 well plate (1 × 
106/Well) were transiently transfected with vectors expressing PDGFRβ wt, 
and PDGFRβ T681I and PDGFRβ D850V, and with the CycD1-Luc vector  
(Vitagliano et al, 2004) containing -1745 bp of the human cyclin D1 promoter 
upstream from the Firefly luciferase cDNA. Twenty-four hours after 
transfection, cells were serum-starved and 100 ng/ml PDGFRBB were added to 
PDGFRβ wt and PDGFRβ T681I transfected cells. For all the assays, 10 ng of 
pRL-null (a plasmid expressing the enzyme Renilla luciferase from Renilla 
reniformis) was used as an internal control. Firefly and Renilla luciferase 
activities present in cellular lysates from cells were assayed using the Dual-
Luciferase reporter system (Promega Corporation, Madison, WI) using the 
LUMAT LB9507 luminometer (EG&G Bethold, MD, USA) and luciferase 
activity was recorded. The readings were expressed as percentage of residual 
activity compared with untreated cells. 
 
3.8 Tumor growth in athymic mice 
3–4 week old BALB/c nu/nu mice (n = 14) obtained from the Jackson 
Laboratory, Bar Harbor, ME, USA, were maintained under aseptic conditions 
and cared in accordance with institutional guidelines. All manipulations were 
performed while mice were under isoflurane gas anesthesia. No mouse showed 
signs of wasting or other signs of toxicity. TT cells (1 x 107/mouse) were 
inoculated subcutaneously into the right dorsal portion. When tumors measured 
70 mm3, after approximately 30 days, mice were randomized to receive BAY 
43-9006 (n = 7, 60 mg/kg/day) or vehicle (n = 7, Cremophor EL–ethanol) alone 
by oral gavage for 5 consecutive days/week for 3 weeks. Tumor diameters were 
measured at regular intervals with calipers. Tumor volumes (V) were calculated 
with the formula: V = A x B2/2 (A = axial diameter; B = rotational diameter). 
Mice were killed by cervical dislocation, and tumors were excised and divided 
in two parts. Half of the tissue was snap-frozen in liquid nitrogen and used for 
protein extraction. The other half was fixed overnight in neutral buffered 
formalin and processed by routine methods. Paraffin-embedded blocks were 
sliced into 5-µm sections and stained by hematoxylin and eosin for histological 
examination or processed for immunohistochemistry.  
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3.9 Statistical Analysis 
All the experiments were performed in triplicates and the average results of 
three independent assays ± standard deviation are indicated. Student’s t test 
was used to assess if null hypothesis is true. Kinase activity curves were 
graphed using the curve-fitting PRISM software (GraphPad Software). To 
compare cell growth we used the unpaired Student’s t test (normal distributions 
and equal variances) and the JMP software program (version 5.1.1; SAS 
Institute, Inc, Austin, TX). To compare tumor growth we used the paired 
Student’s t test (normal distributions and equal variances) and the JMP 
software program (version 5.1.1; SAS Institute), an analysis of variance (linear 
mixed-effect model) test for repeated measures and the Wilcoxon’s rank-sum 
test and the Instat software program (GraphPad Software). All P values were 
two-sided, and differences were statistically significant at P <. 02. 
 
 40 
4. RESULTS AND DISCUSSION 
 
4.1 RET Mutations induce resistance to ZD6474 (manuscript A) 
 
 
4.1.1 Alignment of protein kinase domains. 
Understanding the mechanism of resistance can help to better design small 
molecule inhibitors to target oncogenic kinases and better select patients to be 
treated. There are mutations, for which kinase inhibitors are not effective. One 
of them is mutation T315I (Branford et al. 2002), which occurs at the “gate” of 
the ATP-binding domain (V Hanks domain) of the ABL protein and induces 
kinase resistance to imatinib. This mutation has been called the "gate-keeper" 
mutation, because this residue acts as a gate-keeper of the ATP-binding 
domain. The corresponding residue mediates sensitivity to the corresponding 
kinase inhibitors (Markus et al. 2003, Blencke et al. 2003). Since the kinase 
domain sequences are evolutionary conserved, we performed a comprehensive 
inspection of the domains of RET and ABL protein kinases by aligning the 
homologous domain sequences (Figure 11)  
 
Figure 11 
 
Figure 11 Alignment of RET and ABL kinase sequences in the P-loop (nucleotide binding 
loop) and A-Loop (Activation loop). 
 
 
As shown, some mutations that render the ABL kinase resistant to imatinib 
correspond to mutations that are found in MEN2 carcinoma patients. Mutations 
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E279K, L301F, T315I, F317L, G372R, E373K and L387M in the ABL kinase 
correspond to mutations E768D, L790F, V804M, Y806C, A883F, E884K and 
D898V in RET. Since RET inhibitors are being tested in patients it is important 
to identify the residues that can mediate resistance. Examining the effect of 
these mutations towards sensitivity for RET kinase inhibitors may help in 
understanding resistance mechanism and override this problem. 
 
 
4.1.2 Identification of RET residues that mediate resistance  
To identify amino-acid substitutions in the kinase domain that might possibly 
induce “drug-resistance” to RET inhibitors, we transiently transfected HEK293 
cells with pBABE- based vectors encoding RET/E768D, RET/L790F, 
RET/Y791F, RET/A883F, RET/S891A, RET/C634R, RET/M918T, 
RET/V804M, RET/V804L and Y806C cDNAs (Figure 12). RET/MEN2 
oncoproteins, RET/C634R and RET/M918T, which are known to be efficiently 
inhibited by the compounds PP1 and ZD6474 (Carlomagno et al. 2002b 
&2002a), were used as controls.  
 
Figure 12 
 
 
 
Figure 12. Schematic representation of the RET mutants used in this study. SP: Signal peptide, 
EC: extra-cellular domain, IC: intra-cellular domain, TM: transmembrane domain. 
 
 
Before harvesting, cells were treated for 2h with vehicle, 0.5 and 5.0 µM PP1 
or ZD6474. To determine phosphorylation status, proteins were immunoblotted 
with “phosphorylation-specific” anti-RET antibody (anti-pY1062), able to 
recognize RET proteins only when phosphorylated on tyrosine 1062. Tyrosine 
1062 is responsible for most of RET dependent downstream signaling, it 
functions as a multidocking site for several phosphotyrosine binding (PTB) 
domain containing proteins including SHC, IRS1, Dok, and FRS2 (reviewed in 
Manie et al. 2001). The proteins were also immunoblotted with 
phosphorylation-specific anti-RET-pY905, which maps to the activation loop 
of the kinase (Iwashita et al. 1996) (results not shown). Figure 13 (and 
manuscript A) shows that according to their oncogenicity all RET mutants 
exerted “ligand-independent” autophosphorylation. Mutants RET/E768D, 
RET/L790F, RET/Y791F, RET/A883F, RET/S891A, showed a sensitivity 
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profile to both the compounds PP1 and ZD6474 similar to RET/C634R and 
RET/M918T. The RET phosphorylation is almost completely abrogated at the 
concentration 0.5 µM PP1 and ZD6474. RET expression levels were 
normalized by immunoblotting with a RET specific antibody. 
 
 
Figure 13 
 
 
 
 
Figure 13. Protein extracts from HEK293 cells transiently transfected with the indicated 
constructs and treated for 2 h with vehicle, PP1 or ZD6474 (0.5 or 5µM) were immunoblotted 
with anti-pY1062 and -RET antibodies. 
 
4.1.3 Resistance to ZD6474 by Valine 804 and Tyrosine 806 RET mutants 
in vivo 
The mutations substituting valine 804 either to leucine or to methionine 
(V804L or V804M) rendered the RET kinase significantly resistant to PP1 and 
ZD6474. Virtually no inhibition was detected at the concentration 0.5µM and 
only a modest effect was seen at 5.0 µM. The results are depicted in Figure 14 
(and manuscript A). 
 
Figure 14 
 
 
 
Figure 14. Proteins from HEK293 cells were immunoblotted with anti-pY1062 RET antibodies. 
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In addition to V804M or V804L mutations, substitution of tyrosine to cysteine 
at position 806 was tested for sensitivity towards ZD6474 inhibition. It was 
previously reported that mutations V804M and Y806C co-exist in one patient 
with a MEN2B-like clinical phenotype including MTC, mucosal neuroma, and 
marfanoid habitus (Iwashita et al. 2000). Since Y806 residue is in close 
proximity to V804, we checked the possible role of Y806 mutation in inducing 
drug resistance. We substituted RET/Y806 with a cysteine in the context of a 
constitutively active RET/C634R mutant, since the Y806C mutation by itself 
was known to be poorly activating. RET/C634R and RET/C634R-V804M 
mutants were used as controls. Before harvesting, cells were treated for 2h with 
vehicle, 0.1, 0.5 and 1µM ZD6474 and then lysed. The phosphorylation status 
was determined (Figure 15) by immunoblotting the proteins with anti-pY1062 
and anti-pY905. RET kinase carrying C634R/Y806C mutation was found to be 
resistant to ZD6474. Very mild inhibition was detected at 1µM concentration. 
RET expression was normalized with antibodies recognizing RET. The results 
are depicted in Figure 15 (manuscript E, in preparation). 
 
 
Figure 15 
 
 
     
 
Figure 15. Protein extracts from HEK293 cells transiently transfected with the indicated 
constructs and treated for 2 h with vehicle and ZD6474 (0.1, 0.5 or 1µM) were immunoblotted 
with specific anti-pY1062 and anti-pY905 RET antibodies. 
 
4.1.4 Resistance to ZD6474 by Valine 804 and Tyrosine 806 RET mutants 
in vitro 
To further confirm the resistance exerted by V804 and Y806 mutants, we 
measured their intrinsic catalytic activity by an in vitro phosphorylation assay. 
We used immunopreciptated RET proteins and the synthetic peptide poly-(L-
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glutamic acid-L-tyrosine) (poly-GT) as a substrate, [γ-32P]ATP, and decreasing 
amounts ZD6474 from 50.0 to 0.05µM, The phophorylated poly-GT was 
spotted on 3MM Whatman paper and counted by scintillation. The results of 
four independent experiments were averaged. Deviation was less than 10% of 
the mean. Results showed that the IC50 value for both RET/V804 mutants was 
found to be 5,000 nM, which is 50-fold higher compared to RET/C634R kinase 
(100 nM) (manuscript A). The IC50 value for RET/C634R-Y806C was found 
to be 933 nM, which is almost 10-fold higher than RET/C634R kinase (Figure 
16) (manuscript E, in preparation). The results of four independent 
experiments were averaged. Deviation was less than 10% of the mean. 
 
 
Figure 16 
 
 
 
Figure 16. In vitro IC50 of ZD6474 for RET/C634R-Y806C was measured by the poly-GT 
phosphorylation assay, 
 
 
 4.1.5 Resistance of cells transformed by RET/V804M or V804L mutants 
To test whether the resistance of V804 mutated RET kinases was also 
translated into a resistance of transformed cells to the growth inhibitory 
properties of the compounds, we measured ZD6474 effects on the growth rate 
of RAT1 fibroblasts stably transformed by RET/C634R, RET/V804M or 
RET/V804L. Growth curves reported in Figure 17 demonstrate that ZD6474 
strongly reduced RAT1/C634R cell growth at 1.0 µM, while at this dose it has 
negligible effects on cells expressing valine 804 mutations. RET/C634R, 
RET/V804M or RET/V804L cell growth was completely blocked by 5.0 µM of 
the compound (Figure 17 and manuscript A).  
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Figure 17 
 
 
 
Figure 17. The indicated RAT1 cell lines stably expressing RET mutants were incubated with 
vehicle, 1.0 or 5.0 µM ZD6474 and counted at different time points. Day 1 was the treatment-
starting day. Data are the mean of two experiments performed in triplicate. Standard deviations 
are indicated. 
 
 
4.1.6 Resistance to ZD6474 of cells expressing RET Y806C mutant 
To test the resistance of Y806 mutated RET kinase to inhibition by ZD6474 we 
performed a RET dependent transcriptional regulation assay. Luciferase is an 
ideal reporter because of the absence of endogenous luciferase activity in 
mammalian cells, and because the functional enzyme is produced immediately 
upon translation (Ow et al. 1986, De wet et al. 1987). We seeded 1 × 106 HeLa 
cells/well in 12-well plate. Twenty-four hours later, cells were transiently 
transfected with 500 ng of vectors expressing RET/C634R, RET/C634R-
V804M, and RET/C634R-Y806C; three hours upon transfection, cells were 
serum starved to lower the basal transcription factor activation, and treated with 
various concentrations of ZD6474 (250nM, 1,000nM, 2,500nM and 5,000nM). 
After 48 hours, cells were lysed directly on the plate after a single wash with 
phosphate-buffered saline. We assayed the resulting cell lysates for luciferase 
activity. Three independent experimental points were performed in each 
experiment. Renilla luciferase was used as an internal control. The readings 
were expressed as percentage of residual activity compared with untreated cells 
(Figure 18) (manuscript E, in preparation). Average results of three 
independent assays ± SD are indicated. Student’s t test was used to assess 
statistical significance. *P<.02. 
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Figure 18 
 
Figure 18. 1x106 HeLa cells were transiently transfected with RET constructs and the AP1-Luc 
vector containing six AP1 binding sites upstream from the Firefly luciferase cDNA. Twenty-
four hours after serum starvation cells were treated with different concentrations of ZD6474 
and percent residual activity of luciferase compared with untreated cells was measured. 
Standard deviations are shown. 
 
As indicated in Figure 18, RET-dependent luciferase expression in cells 
transformed with RET/C634R was inhibited by ZD6474. Thus, luciferase 
activity is almost negligible at the concentration of 1000 nM. Cells transfected 
with RET/C634R-V804M did not show any decrease in luciferase activity, 
confirming that these cells are resistant to kinase inhibition by ZD6474. Also 
cells transfected with RET/C634R-Y806C construct showed no inhibition of 
luciferase activity up to 1000 nM. Then, progressive inhibition is noted at 
concentrations above 1000 nM. The results confirm that the RET/Y806C 
substitution causes resistance to ZD6474. However, the RET/Y806C kinase 
could be inhibited at higher ZD6474 concentrations. We also tested the 
inhibition profile of RET mutants carrying both V804M and Y806C 
substitutions and found that it was resistant as the V804M mutant to ZD6474 
inhibition (results not shown). 
 
 
4.2 BAY 43-9006 Inhibition of Oncogenic RET Mutants (manuscript B) 
 
4.2.1 BAY 43-9006 effects on oncogenic RET autophosphorylation in vitro 
BAY 43-9006 or Sorafenib or Nexavar is a novel biaryl urea, discovered by 
Onyx and Bayer pharmaceuticals using a combination of medicinal and 
combinatorial chemistry approaches. Recently the FDA approved this drug for 
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advanced renal cell carcinoma in phase III clinical trials. Sorafenib efficiently 
inhibited the kinase activity of both c-RAF and BRAF (wild type and V600E 
mutant). It is also known to inhibit downstream MEK and ERK 
phosphorylation in various cancer cell lines and tumor xenografts and exhibited 
potent oral antitumor activity in a broad spectrum of human tumor xenograft 
models. Further characterization of sorafenib revealed that this molecule was a 
multi-kinase inhibitor that targeted the vascular endothelial growth factor 
receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor 
receptor family (PDGFRβ and KIT) (Wilhelm et al. 2004).  
Since this compound proved its efficacy against numerous kinases, we 
thought it is appropriate to test its effect against RET. We used an “in vitro 
autophosphorylation assay” to determine whether BAY 43-9006 inhibited the 
autophosphorylation of the RET/C634R kinase. Protein extracts from NIH3T3 
cells stably transfected with RET/C634R were immunoprecipitated with rabbit 
polyclonal anti-RET antibody and subjected to an immunocomplex kinase 
assay in the presence of [γ- 32P] ATP. BAY 43-9006 or vehicle (DMSO) alone 
was added to the reaction mixture to reach the desired concentrations (20nM, 
50nM, 100nM, 100nM, 500nM and 1000nM). Reaction products were 
separated by 10% sodium dodecyl sulfate– polyacrylamide gel electrophoresis, 
and phosphorylated proteins were detected by autoradiography and quantified 
using a PhosphorImager. BAY 43-9006 inhibited RET/C634R 
autophosphorylation with an IC 50 of roughly 50 nM. The results are reported 
in manuscript B. 
Thus, we performed a second in vitro enzymatic assay to measure the 
ability of RET/C634R to phosphorylate a synthetic poly-GT substrate. Protein 
extracts from NIH-RET/C634R cells were immunoprecipitated with the anti-
RET antibody and subjected to a kinase assay with poly-( L -glutamic acid- L -
tyrosine (poly-GT) as a synthetic substrate in the presence of [γ-32P]ATP and 
different concentrations of vehicle or BAY 43- 9006. The phosphorylated poly-
GT was spotted on 3MM filter paper, and radioactivity was counted by 
scintillation. The results are reported as residual poly-GT phosphorylation 
levels compared with the control (DMSO). The concentration of drug that 
inhibited activity by 50% (IC 50) is shown (Figure 19). Each point represents 
the mean value from four independent determinations; error bars represent 95% 
confidence intervals. BAY 43-9006 blocked the activity of RET/C634R with an 
IC 50 of 47 nM. 
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Figure 19 
 
 
Figure 19. In vitro IC50 of BAY 43-9006 for RET/C634R.  
 
 
4.2.2 BAY 43-9006 inhibits RET autophosphorylation in vivo 
To determined whether BAY 43-9006 could also inhibit the kinase activity of 
wild type and mutant RET in intact cells, we treated serum-starved cells (24 
hours) NIH3T3 fibroblasts expressing two oncogenic versions of RET 
(RET/C634R, or RET/ M918T) or RET wild type with its coreceptor GFRα1 
(Figure 20) with different concentrations of BAY 43-9006 for 2 hours. Ten 
minutes prior to the treatment NIH3T3 cells expressing RET wild type were 
stimulated with GDNF. We then measured RET phosphorylation levels by 
immunoblotting with α pY905 and with anti-RET (αRET) as a control for 
protein loading and transfer. The results are reported in manuscript B 
Treatment with BAY 43-9006 reduced the phosphotyrosine content of 
RET/C634R, and RET/M918T with an IC 50 of 20 – 50 nM. RET kinases were 
almost completely inhibited by 100 nM BAY 43-9006.  
 
 
Figure 20 
 
 
Figure 20. Schematic representation of the various constructs; EC = Extracellular domain; IC = 
Intracellular domain TM = transmembrane domain 
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4.2.3 Inhibition of RET transformed cells proliferation by BAY 43-9006 
We studied the effects exerted by BAY 43-9006 on the growth of NIH3T3 cells 
transformed by RET/C634R or RET/M918T grown in low serum (1%) for 10 
days. Proliferation of NIH3T3 cells transformed with these RET mutants was 
virtually arrested after treatment with 1 µM of BAY 43-9006 (Figure 21). 
Constitutively active oncogenic versions of RET activate the RAS/RAF/MAPK 
pathway by recruiting Grb2/Sos complexes through the SHC protein (Santoro 
et al. 2004, Asai et al. 1996). Accordingly, to verify whether this inhibition in 
cell growth is correlated with SHC and p44/p42MAPK phosphorylation, we 
measured the MAPK/SHC phosphorylation levels by immunoblotting with 
phospho-specific antibodies. BAY 43-9006 inhibited oncogenic RET 
dependent phosphorylation of SHC and p44/42MAPK with an IC50 of 
approximately 50 nM (results not shown). Hence, BAY 43-9006 antagonized 
RET oncogenic activity by blocking its kinase function, signaling and 
mitogenic effects. 
 
Figure 21 
 
 
 
Figure 21. The indicated NIH3T3 cell lines stably expressing RET mutants were incubated 
with DMSO or 1.0 µM BAY 43-9006 in 1% calf serum, and the cells were counted at different 
time points. Each point represents the mean value for five dishes, and error bars represent 95% 
confidence intervals. P values were determined by the two-tailed unpaired Student’s t test. * P 
<.001. 
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4.2.4 Effects of BAY 43-9006 on human carcinoma cells harboring RET 
oncogenes 
We investigated the effects of BAY 43-9006 on the mitogenic signalling in TT 
cell line, which is derived from a human MTC harboring the RET/C634W 
mutation (Carlomagno et al. 1995). Treatment of TT cell line with 100 nM 
BAY 43-9006 almost completely abrogated RET and SHC phosphorylation 
(Figure 22). This treatment also abrogated p44/p42 MAPK phosphorylation in 
TT cells (Figure 22 and manuscript B). 
 
Figure 22 
 
 
 
Figure 22. Inhibition of RET-mediated signaling by BAY 43-9006 in human cells. TT cell lines 
were serum-starved for 24 hours and then treated with vehicle or BAY 43-9006. Cell lysates 
(50µg) were immunoblotted with rabbit polyclonal anti-phospho-RET (αp905), and anti-RET 
(αRET). 
 
We next measured the growth rate of TT (grown in 10% serum) cells treated 
with three different concentrations of BAY 43-9006. No growth was observed 
at 1000 nM BAY 43-9006. The number of TT cells after 10 days of treatment 
with 250 nM BAY 43-9006 was considerably lower than the cells treated with 
vehicle. We also observed growth inhibition at 100 nM BAY 43-9006 (Figure 
23). 
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Figure 23 
 
 
 
Figure 23. TT cells were incubated with vehicle, 100, 250, 1000 nM BAY 43-9006 in 10% 
serum and counted at different time points. Each point represents the mean value of five dishes 
and error bars represent 95% confidence intervals. P values are determined using the two-tailed 
unpaired Student’s t test. *p<.002. 
 
 
The TT cells showed a marked G1 arrest, upon treatment with 1 µM BAY 43-
9006. Thus, BAY 43-9006 blocks oncogenic RET signaling in TT cells causing 
mainly cytostatic effect (manuscript B). 
 
 
4.2.5 BAY 43-9006 inhibition of TT-induced tumor growth in nude mice 
In order to investigate the effects of BAY 43-9006 on MTC tumor growth, we 
injected nude mice (subcutaneous, right dorsal) with 1 × 10 7 TT cells. TT cells 
are tumorigenic in nude mice. After approximately 30 days, when tumors 
measured approximately 80 mm3, mice (seven in each group) received BAY 
43-9006 (60 mg/kg/day) or vehicle (Cremophor EL – ethanol) by oral gavage 5 
days/week for 3 weeks. Tumor diameters were measured with calipers, and 
tumor volumes were calculated. Treatment with BAY 43-9006 strongly 
reduced tumor growth (manuscript B). After 21 days, the mean volume of 
tumors in mice treated with BAY 43-9006 decreased (from 72.5 to 44 mm3, 
difference = 28.5 mm3, 95% CI = 7 mm3 to 50 mm3; P = .018), whereas of 
mice treated with vehicle increased (from 87 to 408 mm3, difference = 320 
mm3, 95% CI = 180 mm3 to 460 mm 3; P <.001). Treated tumors showed a 
cytoreduction, probably because of the extensive necrosis occurred upon 
treatment. Ki67/MIB-1 immunostaining was reduced in treated tumors, which 
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is consistent with a reduced mitotic index (not shown). Moreover we observed 
a strong reduction of in vivo RET phosphorylation in proteins that were 
extracted from tumors in BAY 43-9006-treated versus vehicle-treated mice 
(manuscript B). 
 
 
4.2.6 Inhibition of RET/V804 and RET/V806 mutants by BAY 43-9006  
As shown in the first section, mutations of valine 804 in RET to leucine 
(V804L) or methionine (V804M) render RET resistant (approximately 50-fold 
increase of the IC 50) to the small-molecule tyrosine kinase/RET inhibitors PP1 
and ZD6474 (Carlomagno et al 2004). Here is also reported that change of 
tyrosine 806 to cysteine renders RET resistant (approximately 25-fold increase 
of IC 50) to ZD6474 (Figure 24). 
 
 
 
Figure 24 
 
 
 
 
Figure 24. Schematic representation of RET/V804L, RET/V804M, RET/Y806C and 
RET/C634R mutants. EC = extracellular domain; IC = intracellular domain; TM = 
transmembrane domain. 
 
In order to test the effects of BAY 43-9006 on RET/V804L or RET/V804M 
mutants, we treated intact RAT1 fibroblasts expressing the RET/V804L or the 
RET/V804M alleles, with vehicle, BAY 43-9006, or PP1 (500 or 1000 nM), for 
2 hours and RET phosphorylation was measured by immunoblotting. Only 
residual phosphorylation of the two mutant proteins (more pronounced for 
V804M) was detected after treatment with 500 nM BAY 43-9006 (Figure 25). 
Mutant RET phosphorylation was virtually abrogated by 1000 nM BAY 43 
9006. 
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Figure 25 
 
 
Figure 25. Protein extracts from RAT cells expressing the indicated constructs and treated for 2 
hours with DMSO, BAY 43-9006, or PP1 were immunoblotted with rabbit polyclonal anti-
phospho- RET or anti-RET antibodies. 
 
We have also tested inhibition of Y806C mutant upon treatment with BAY 43-
9006. We treated HEK-293 cells transfected with RET/C634R and 
RET/C634R/Y806C mutants, with vehicle, 100 nm, 500 nm and 1000 nm BAY 
43-9006. Residual RET phosphorylation was detected by immunoblotting with 
αpY1062 antibody. RET/C634R/Y806C phosphorylation was virtually 
abrogated by 500 nM BAY 43-9006 whereas RET/C634R phosphorylation was 
already hindered at 100 nM (Figure 26). We also investigated the effects of 
BAY 43-9006 on intracellular signalling. Treatment of HEK293 cells 
transfected with RET/C634R with 100 nM BAY 43-9006 almost completely 
abrogated SHC phosphorylation (Figure 26). The treatment of HEK293 cells 
transfected with RET/C634R-Y806C with 100 nM BAY 43-9006 did not 
exerted any effect on SHC phosphorylation (Figure 26). Only 500 nM 
obstructed RET/C634R-Y806C signalling significantly. 
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Figure 26 
 
 
 
Figure 26 A) Protein extracts from HEK293 cells transfected with indicated constructs and 
treated for 2 hours with DMSO and BAY 43-9006 were immunoblotted with rabbit polyclonal 
anti-phospho- RET (α pY1062) or anti-RET (α RET) antibodies. B) Inhibition of RET-
mediated signaling by BAY 43-9006 in HEK293 cells transfected with the indicated constructs. 
Cell lysates (50µg) were immunoblotted with rabbit polyclonal anti-phospho-SHC (αpSHC) 
and SHC (αSHC) antibodies as a control for protein loading and transfer. Representative blots 
from two independent experiments are shown. 
 
 
We also measured the effect of BAY 43-9006 on the activity of RET/V804L, 
RET/V804M and RET/C634R/Y806C kinases using the in vitro poly-GT 
kinase assay. Despite their resistance to other inhibitors, all mutants were only 
two- to threefold less sensitive than RET/C634R to inhibition by BAY 43-
9006. The IC 50 of BAY 43-9006 was 110 nM for RET/V804L, 147 nM for 
RET/V804M (manuscript B), and 100 nM for RET/C634R/Y806C (data not 
shown), whereas the IC 50 of BAY 43-9006 for RET/C634R was 49 nM. 
Finally we studied the effects exerted by BAY 43-9006 on the growth rate of 
RAT1 cells transformed by RET/V804M and RET/C634R (Figure XXXIV). 
RET/C634R cell growth was inhibited with 0.1 µM BAY 43-9006. Similarly, 
RET/V804M cell growth was inhibited with 0.1 µM BAY 43-9006. The 
proliferation of RAT1 fibroblasts expressing either RET/C634R or 
RET/V804M was virtually abrogated after treatment with 1 µM BAY 43-9006. 
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Figure 27 
 
 
 
Figure 27. RAT1 cells expressing the indicated construct were incubated with DMSO, BAY 
43-9006, or PP1 in 1% serum and counted at different time points. Each point represents the 
mean value of five replicates and error bars represent 95% confidence intervals. P values were 
determined using the two-tailed unpaired Student’s t test. * P <.001. 
 
 
4.3 BAY 43-9006 inhibition of oncogenic PDGFRβ  and KIT Mutants  
 
4.3.1 Sequence alignment of ABL, RET, KIT and PDGFRβ  
Imatinib (imatinib mesylate, STI571, Gleevec or Glivec) inhibits KIT (in vitro 
IC50=410 nM) and PDGFR (in vitro IC50=380 nM). Consequently, it has been 
successful in the treatment of cancer patients carrying activating KIT or 
PDGFR mutations (Druker 2004). A frequent cause of resistance to imatinib in 
CML is a threonine-315-to-isoleucine substitution (T315I) in BCR-ABL. T315 
residue is located in the ATP-binding pocket at the gate-keeper position. 
Mutations of the corresponding residue in KIT (T670I) and PDGFR (T674I in 
PDGFRα and T681I in PDGFRβ) also cause imatinib resistance (Tamborini et 
al. 2004, Cools et al. 2003). Moreover, KIT and PDGFRα variants carrying 
mutations in the kinase activation loop (D816 in KIT and D842 in PDGFRα, 
which corresponds to D850 in PDGFRβ) are refractory (primary resistance) to 
imatinib. Therefore, mastocytosis and GIST patients with these mutations 
respond poorly to imatinib (Corless et al. 2005).  
It is known that BAY 43-9006 targets several serine/threonine and 
receptor kinases in both tumor cells and the tumor vasculature. These kinases 
include PDGFR-β and KIT (Lyons et al. 2001, Wihelm et al. 2004). The IC50 
of BAY 43-9006 for KIT and PDGFRβ is 68 and 57 nM, respectively 
(Wilhelm et al, 2004). Since BAY 43-9006 efficiently inhibits RET gate-
keeper mutations (V804M/L), it is relevant to verify its inhibition efficacy 
towards KIT and PDGFR mutant kinases which are resistant to imatinib 
(Figure 28).  
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Figure 28 
 
A 
 
 
 
B 
 
 
Figure 28. Schematic representation of ABL, RET, PDGFRβ and KIT domain sequences 
alignment. P- loop – nucleotide-binding loop, A-loop – Activation loop. 
 
 
4.3.2 BAY 43-9006 effects on PDFGRβ  and KIT mutants in vitro 
Thus, we tested if BAY 43-9006 inhibits imatinib-resistant KIT and PDGFRβ 
kinases that have mutations in the gate-keeper residue (KIT T670I and 
PDGFRβ T681I) or in the activation loop (KIT D816V and PDGFRβ D850V) 
(Figure 29).  
 
 
Figure 29 
 
Figure 29. Schematic representation of the KIT and PDGFRβ mutants studied. The black bars 
indicate the transmembrane domain. 
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In an in vitro kinase assay, CMV-6 vectors expressing the mouse KIT T670I 
and KIT D816V mutants were subjected to in vitro autophosphorylation by 
incubating the immunocomplex with kinase buffer, 32P-radiolabeled ATP and 
different concentrations of BAY 43-9006 (sorafenib) as indicated in Figure 29. 
We found that the drug strongly inhibited the KIT T670I gatekeeper mutant 
(IC50 = 60 nM), but was less active on the D816V activation loop mutant (IC50 
= 3.8 µM) (Figure 30) (manuscript D, submitted). An in vitro kinase assay 
with a GST-KIT (TK) recombinant protein carrying the D816V mutation 
confirmed these findings (data not shown). 
 
Figure 30 
 
 
 
Figure 30. In vitro autophosphorylation assay. The average results of three experiments 
performed in duplicate ± SD are reported. The inhibitory concentration 50 (IC50) for each 
protein is indicated. 
 
We performed a similar assay for PDGFRβ mutants. HEK293 cells were 
transiently transfected with pcDNA 3.1 vectors encoding PDGFRβ T681I and 
D850V mutants and proteins were immunoprecipitated and subjected to in vitro 
autophosphorylation assay. Also the PDGFRβ gatekeeper mutant (T681I) was 
found to be potently inhibited by BAY 43-9006 (sorafenib) in vitro (IC50 = 
0.11µM). Moreover, similar to the D816V KIT mutant, the PDGFRβ activation 
loop mutant (D850V) was less efficiently inhibited (IC50 = 1.17µM) (Figure 
30) (manuscript D, submitted). 
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Figure 31 
 
 
 
Figure 31. In vitro autophosphorylation assay. The average results of three experiments 
performed in duplicate ± SD are reported. The inhibitory concentration 50 (IC50) for each 
protein is indicated. 
 
 
4.3.3 Effect of BAY 43-9006 on KIT and PDGFRβ  mutants in intact cells 
We tested the inhibitory effects of BAY 43-9006 (sorafenib) on KIT and 
PDGFRβ mutant autophosphorylation in intact cells. HEK293 cells were 
transiently transfected with either wild-type, gate-keeper, or activation loop 
mutant receptors KIT (T670I, D816V) or PDGFRβ (T681I and D850V). 
Twenty-four hours after transfection, cells were serum-starved. Two hours 
before being harvested, cells were treated with different concentrations (0.1, 
0.5 and 1 µM) of BAY 43-9006. KIT wt and KIT T670I transfected cells were 
stimulated with 100 ng/ml SCF for 10 minutes, whereas PDGFRβ wt and 
PDGFRβ T681I transfected cells were stimulated with 100 ng/ml PDGF BB for 
10 minutes, because they did not display detectable basal phosphorylation 
levels. Instead, consistent with their oncogenic properties, activation loop 
mutants displayed constitutive kinase activity, and did not require ligand 
stimulation (Fletcher 2004). As shown in Figure 32, BAY 43-9006 was very 
effective in blocking wild-type KIT and PDFGRβ phosphorylation. 100 nM 
BAY 43-9006 blocked receptor phosphorylation by 90%. Moreover, gate-
keeper mutants were almost as sensitive as wild-type proteins to BAY 43-9006 
(100nM BAY 43-9006 blocked KIT T670I and PDGFRβ T681I receptor 
phosphorylation in intact cells by 80%). The drug was clearly less active 
against the activation loop mutants, 1 µM BAY 43-9006 inhibited KIT D816V 
and PDGFRβ D850V by about 70%, whereas the effect of 100 nM was barely 
detectable. Still, BAY 43-9006 appeared more active than imatinib, because 1 
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µM imatinib had virtually no effect on KIT D816V and PDGFRβ D850V as 
reported by others (Growney et al. 2005, Corless et al. 2005). 
 
Figure 32 
 
 
 
Figure 32. Effect of BAY 43-9006 on KIT and PDGFRβ gatekeeper and activation loop 
mutants in intact cells. 
 
 
4.3.4 Inhibition of PDGFRβ and KIT signaling by BAY 43-9006 
In a preliminar set of experiments, we have noted that PDGFRβ triggered 
transcription of a luciferase (LUC) reporter downstream from Cyclin D1 (Cyc 
D1) promoter in the HeLa cells. To verify BAY 43-9006 activity, we evaluated 
whether the drug blocked receptor activity on this promoter. CycD1-LUC 
promoter activity was inhibited (∼ 40 fold reduction) when PDGFRβ and 
PDGFRβ T681I cells were treated with 1 µM BAY 43-9006 (*P <.02). 
Although BAY 43-9006 was less active on the activation loop mutants of 
PDGFRβ, it still exerted significant inhibitory activity at 1 µM (∼7 fold 
reduction of PDGFRβ D850V) (P <. 02) (Figure 33) (manuscript D, 
submitted).  
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Figure 33 
 
 
 
Figure 33. HeLa cells were transiently transfected with vectors expressing PDGFRβ wt, and 
PDGFRβ T681I and PDGFRβ D850V, and with the CycD1-Luc vector. The cells were treated 
for 24h with 1µM BAY 43- 9006 and imatinib. Cells transfected with PDGFRβ T681I mutant 
were stimulated with ligand. The results are expressed as percentage of residual activity 
compared with untreated cells. Average results of three independent assays ± SD are indicated. 
Student’s t test was used to assess statistical significance. *P<.02. 
 
To verify BAY 43-9006 activity on KIT mutants, we evaluated whether the 
drug blocked receptor activity on KIT dependent AP1-LUC promoter in 
NIH3T3 fibroblasts. The AP1-LUC reporter activity was blocked (∼ 10 fold 
reduction) when KIT and KIT T670I cells were treated for 24 hours with 1 µM 
BAY 43-9006 (Figure 34). Although BAY 43-9006 was less active on the 
activation loop mutants, it still exerted significant inhibitory activity at 1 µM 
(∼2 fold reduction of KIT D816V) (P <. 02) (Figure 34) (manuscript D, 
submitted). Therefore in conclusion BAY 43-9006 was able to overcome 
resistance mediated by mutations at the gate-keeper residue not only in the case 
of RET but also KIT and PDGFR. The drug exerted some effect alsthough ore 
modest also in the case of KIT nd PDGFR mutants at the activation loop 
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Figure 34 
 
 
 
 
Figure 34. NIH 3T3 cells were transiently transfected with vectors expressing KIT wt, KIT 
T670I and KIT D816V, and with the AP1-Luc vector. The cells were treated for 24h with 1µM 
BAY 43- 9006 and imatinib. Cells transfected with KIT T670I mutant were stimulated with 
ligand. The results are expressed as percentage of residual activity compared with untreated 
cells. Average results of three independent assays ± SD are indicated. Student’s t test was used 
to assess statistical significance. *P<.02. 
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5. CONCLUSIONS 
Several compounds exert an inhibitory effect on RET (Carlomagno et al. 2002a, 
2002b, & 2003, Carniti et al.  2003, Strock et al. 2003, Cuccuru et al.  2004, 
Ezzat et al. 2005). Among these, ZD6474 appears to be particularly promising, 
and is now undergoing phase II testing in patients with RET-mutation-positive 
familial MTC. Resistance to small molecule kinase inhibitors has emerged as a 
major drawback of their clinical use (Cools et al. 2005). In this study we have 
addressed the mechanism of RET resistance to ZD6474 and the possibility of 
overcoming such a resistance with second line inhibitors. We show that, while 
most RET mutants are susceptible to inhibition, RET proteins carrying 
mutations at residue V804 (V804L and V804M) and Y806 (Y806C) are 
resistant to ZD6474. In fact, the IC50 of ZD6474 increased about 50-fold for 
the V804L and V804M mutations and 10-fold for the Y806C mutant. 
Noteworthy, residues in SRC (Bishop et al. 2000), EGFR (Blencke et al. 2003, 
Ciardiello et al.  2003), ABL (Schindler et al. 2000, Gorre et al. 2001, La Rosee 
et al. 2002, Nagar et al. 2002, Shah et al. 2002), KIT and PDGFR 
corresponding to V804 in RET dictates susceptibility of these kinases to the 
corresponding inhibitors. For this reason that residue has been called the “gate-
keeper”. Crystal structures have shown that inhibitor moieties extend into a 
hydrophobic cavity of the ATP-binding site that is not occupied by the ATP 
itself. The residues mapping in that particular position lie in this cavity and, 
likely, the presence of space-filling bulky amino acids in that position 
abrogates efficient inhibitor binding. The close position of tyrosine 806 and 
valine 804, likely accounts for resistance-mediating Y806 mutations in RET. It 
has been also shown that, mutations at F317 in BCR/ABL, which corresponds 
to Y806 in RET, confer strong resistance to PD166326 (a pyrido-pyrimidine 
compound), but at the same time do not considerably interfere with inhibition 
by imatinib (Von Bubnoff et al. 2005). 
A peculiar feature of the RET system described here is that resistance-
causing mutations are not selected during treatment (like in the case of 
BCR/ABL), rather they are spontaneously occurring at the germline or somatic 
level, causing constitutive activation of RET and cancer formation (Pasini et al. 
1997, Iwashita et al. 1999). V804 mutations are present alone or with other 
RET mutations in MEN2 carriers (4% of the cases) and in sporadic MTC cases 
(Lesueur et al. 2005). The Y806 mutation has been reported in one single 
cancer patient (Miyauchi et al. 1999). Therefore, it appears that these mutations 
at the same time activate the ligand-independent function of the RET kinase 
and mediate resistance to inhibitory compounds. In the light of our findings, 
V804 and Y806 mutation positive tumors are expected to display primary 
resistance to ZD6474. However, it is also conceivable that these mutations 
could also play a role in acquisition of secondary resistance, so that, upon 
treatment, a tumor originally negative for the mutation can select clones 
carrying the RET/V804 or Y806 substitution and therefore no longer respond to 
the therapy. 
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The search of second line inhibitors might help to overcome the 
problem of resistance formation. In our study we isolated an additional RET 
inhibitory compound, eg. BAY 43-9006 (sorafenib) (Lyons et al. 2001, 
Wilhelm et al. 2004) and demonstrated that drug-resistant RET mutants 
(V804L, V804M and Y806C) only slightly (a 2- and 3-fold increase in IC50, 
respectively) affected RET susceptibility to BAY 43-9006.  These results may 
be of clinical importance and a switch to BAY 43-9006 might be envisaged to 
treat patients who are resistant or develop resistance due to a mutation at 
position Y806 or V804 in RET. Combination with ZD6474 might also be 
envisaged to reduce the risk of the emergence of treatment-resistant clones 
Obviously, we cannot exclude that RET mutants, other than those tested in this 
study, may have resistance to the BAY 43-9006. 
BAY 43-9006 targets kinases other than RET, including KIT and 
PDGFRβ. Hence, we decided to verify whether it could inhibit KIT and 
PDGFRβ kinases resistant to imatinib. Gate-keeper mutants of both KIT and 
PDGFRβ are efficiently inhibited by BAY 43-9006, with an IC50 (60 nM for 
KIT T670I and 110 nM for PDGFRβ T681I) well below the average plasma 
concentration of the drug (unbound compound: 1-2 µM). While this work was 
in progress, Lierman and co-workers demonstrated the efficacy of BAY 43-
9006 on an oncogenic rearranged form of PDGFRα carrying the gate-keeper 
mutation (T674I) (Lierman et al. 2006). All together these data suggest that 
BAY 43-9006 may represent a therapeutic alternative for patients displaying 
KIT and PDGFRα/β gate-keeper mutations and combination with imatinib 
might be envisaged to reduce the risk of the emergence of treatment-resistant 
clones.  
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Disease associated mutations at valine 804 in the RET receptor tyrosine
kinase confer resistance to selective kinase inhibitors
Francesca Carlomagno1, Teresa Guida1, Suresh Anaganti1, Giancarlo Vecchio1, Alfredo Fusco1,
Anderson J Ryan2, Marc Billaud3 and Massimo Santoro*,1
1Dipartimento di Biologia e Patologia Cellulare e Molecolare, University ‘Federico II’, c/o Istituto di Endocrinologia ed Oncologia
Sperimentale del CNR, via S. Pansini 5, Napoli, Italia; 2Cancer Discovery, Astra Zeneca Mereside, Alderley Park, Macclesfield,
Cheshire, UK; 3Laboratoire de Genetique, CNRS, Lyon, France
We have recently demonstrated that the pyrazolopyrimi-
dines PP1 and PP2 and the 4-anilinoquinazoline ZD6474
display a strong inhibitory activity (IC50p100 nM)
towards constitutively active oncogenic RET kinases.
Here, we show that most oncogenic MEN2-associated
RET kinase mutants are highly susceptible to PP1, PP2
and ZD6474 inhibition. In contrast, MEN2-associated
swap of bulky hydrophobic leucine or methionine residues
for valine 804 in the RET kinase domain causes resistance
to the three compounds. Substitution of valine 804 with
the small amino- acid glycine renders the RET kinase even
more susceptible to inhibition (ZD6474 IC50: 20 nM) than
the wild-type kinase. Our data identify valine 804 of RET
as a structural determinant mediating resistance to
pyrazolopyrimidines and 4-anilinoquinazolines.
Oncogene advance online publication, 7 June 2004;
doi:10.1038/sj.onc.1207810
Keywords: thyroid; tyrosine kinase inhibitors; RET;
MEN2
Introduction
RET is a transmembrane tyrosine kinase participating in
a cell-surface protein complex that binds the glial
derived neurotrophic factor (GDNF) family neurotro-
phins (Manie et al., 2001). Germline point mutations in
RET cause three related dominantly inherited cancer
syndromes: multiple endocrine neoplasia type 2A
(MEN2A), 2B (MEN2B) and Familial Medullary
Thyroid Carcinoma (FMTC) (Online Mendelian In-
heritance in Men, OMIM: #171400). MEN2 patients are
invariably affected by Medullary Thyroid Carcinoma
(MTC), a malignant tumor arising from calcitonin-
secreting C cells of the thyroid (Sherman, 2003).
Additional features can be present in MEN2A (pheo-
chromocytoma and parathyroid adenoma) and MEN2B
(pheochromocytoma, mucosal neuroma and ganglio-
neuroma of the intestine) (Brandi et al., 2001).
Most MEN2B patients carry the M918T substitution
in a domain of the RET kinase, the Pþ 1 loop, in strict
proximity to the activation loop, while only a small
fraction of them harbor the A883F substitution. The
majority of MEN2A and FMTC mutations affects one
cysteine of the extracellular cysteine-rich domain of
RET. Less frequently, FMTC is associated to changes in
the N-terminal (E768D, L790F, Y791F, V804L,
V804M) or C-terminal (S891A) lobe of the RET kinase.
Somatic mutations of V804, M918 and E768 are
frequently found in sporadic MTC, as well (Bolino
et al., 1995; Ponder, 1999).
MEN2-associated RET mutations have a gain of
function effect, promoting ligand-independent activa-
tion of the kinase. This occurs through different
mechanisms depending on the location of the amino-
acid change. Extracellular cysteine mutants display
constitutive kinase activity consequent to disulﬁde-
bonds stabilized ligand-independent dimerization (Asai
et al., 1995; Santoro et al., 1995; Carlomagno et al.,
1997; Ito et al., 1997; Chappuis-Flament et al., 1998).
RET activation by mutations targeting the intracellular
domain is less understood (Santoro et al., 1995; Pasini
et al., 1997; Iwashita et al., 1999). Likely, these
mutations modify the structure of the kinase switch-
ing-on its enzymatic function. In the case of the M918T
mutation, a change in substrate speciﬁcity has also been
proposed (Santoro et al., 1995; Songyang et al., 1995).
Oncogenic activation of RET can also result from
chromosomal inversions or translocations in papillary
thyroid carcinomas that cause the recombination of the
RET TK to heterologous genes (RET/PTC oncogenes)
(Fagin, 2002).
Targeting the enzymatic activity of tyrosine kinases
by small molecule inhibitors is a promising strategy in
human cancer therapy (Zwick et al., 2002). Several
molecules have been successfully used in clinical trials
and one of them, STI571 (imatinib mesylate or Gleevec),
has been approved for treatment of diseases carrying
c-KIT point mutations (Gastrontestinal Stromal
Tumors) (Demetri et al., 2002; Joensuu et al., 2002) or
platelet-derived growth factor receptor (PDGFR) re-
arrangements (Apperley et al., 2002; Sawyers, 2002a;
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Cools et al., 2003). STI571 is now a standard for the
treatment of BCR-ABL positive chronic myeloid
leukaemia (CML) (Druker et al., 1996, 2001; Sawyers
et al., 2002b). However, STI571 treated CMLs often
develop resistance to the drug and relapse occurs.
Selection of clones with mutations targeting residues
that are important for the binding of BCR-ABL to
STI571 is one important mechanism of resistance.
Among the most prevalent resistance-causing mutations
is the substitution of T315 in the BCR-ABL kinase with
isoleucine (Schindler et al., 2000). It remains unclear
whether resistance-causing mutations occur under treat-
ment or rather can be pre-existing and be selected by the
treatment.
We have identiﬁed three tyrosine kinase inhibitors,
the pyrazolopyrimidines PP1 and PP2 and the 4-
anilinoquinazoline ZD6474, with a strong activity
towards RET kinase (IC50p100 nM) (Carlomagno
et al., 2002a, b, 2003). PP1 and PP2 are inhibitors of
SRC and SRC-like kinases (Hanke et al., 1996), while
ZD6474 is a powerful inhibitor of the VEGF receptor
kinase KDR with additional activity against EGFR
(Wedge et al., 2002). The three compounds are able to
block enzymatic activity of RET/C634R and RET/
M918T point mutants and of RET/PTC chimeric
oncoproteins, resulting in the efﬁcient inhibition of their
tumorigenic potential (Carlomagno et al., 2002a, b,
2003).
Understanding mechanism of resistance can help to
better design small molecule inhibitors to target
oncogenic kinases and better select patients to be
treated. Here we have screened a panel of point-
mutations targeting the RET kinase domain in familial
and sporadic medullary thyroid carcinomas for suscept-
ibility to PP1, PP2 and ZD6474. We show that two
naturally occurring mutations of valine 804 of RET
cause resistance to the three compounds, thereby
identifying valine 804 as a key structural determinant
of RET response to small molecule kinase inhibitors.
Results
Inhibition of RET/MEN2 tyrosine kinase domain mutants
in living cells
To test the activity of PP1, PP2 and ZD6474 towards
RET/MEN2 oncoproteins carrying amino-acid substi-
tutions in the kinase domain, we transiently transfected
HEK293 cells with pBABE-based vectors encoding
RET/E768D, RET/L790F, RET/Y791F, RET/V804L,
RET/V804M, RET/S891A and RET/A883F cDNAs
(Figure 1a). As controls, we used RET/C634R and
RET/M918T constructs, known to be efﬁciently inhib-
ited by the three compounds. Before harvesting, cells
were treated for 2 h with vehicle, 0.5 and 5.0 mM PP1,
PP2 or ZD6474 and then lysed. To determine phos-
phorylation status, proteins were immunoblotted with
phosphorylation-speciﬁc anti-RET antibodies, able to
recognize RET proteins only when phosphorylated on
tyrosine 1062 (anti-pY1062) (Figure 1b, c) or tyrosine
905 (anti-pY905) (not shown). Tyrosine 1062 is respon-
sible for most of RET dependent downstream signalling,
functioning as a multidocking site for several phospho
tyrosine binding (PTB) domain containing proteins
including SHC, IRS1, Dok and FRS2 (reviewed in
Manie et al., 2001). Tyrosine 905 maps in the activation
loop of the kinase, its phosphorylation stabilizing the
active conformation of the enzyme (Iwashita et al.,
1996). Figure 1 shows that according to their oncogeni-
city, all the RET mutants exerted ligand-independent
autophosphorylation. Most of the mutants (RET/
E768D, RET/L790F, RET/Y791F, RET/S891A and
RET/A883F) showed a sensitivity proﬁle to the three
compounds very similar to that of RET/C634R and
RET/M918T (Figure 1b). Instead, mutations substitut-
ing valine 804 either to leucine or to methionine (V804L
and V804M) rendered the RET kinase signiﬁcantly
resistant to PP1, PP2 and ZD6474: virtually no
inhibition was detected at 0.5 mM and only a modest
effect was seen at 5.0 mM (Figure 1c). Likely, the bulkier
hydrophobic side chains of leucine and methionine
sterically interferes with the binding of the inhibitors at
the nucleotide binding site of RET.
Resistance to inhibition of valine 804 RET mutants in
vitro
To further evaluate V804 mutants resistance to PP1,
PP2 and ZD6474, we measured their intrinsic catalytic
activity by an in vitro phosphorylation assay. We used
immunoprecipitated RET proteins and the synthetic
peptide poly-(L-glutamic acid-L-tyrosine) (poly-GT) as a
substrate. The assay was performed in the presence of
different concentrations of PP1 and ZD6474. As shown
in Figure 2a, b, while RET/C634R responded very
efﬁciently to PP1 and ZD6474, RET/V804L and RET/
V804M showed a marked increase of residual activity
upon treatment with both compounds. V804 mutant
kinase activity was resistant to PP2, as well (not shown).
A dose–response experiment was performed with
ZD6474. IC50 for both RET/V804 mutants (5.0 mM)
was 50-fold higher compared to RET/C634R kinase
(100 nM) (Figure 2c).
ZD6474 effects on mitogenic activity and signalling of
V804 mutants
RET/MEN2 mutants cause morphological transforma-
tion and stimulate proliferation of immortalized ﬁbro-
blasts (Santoro et al., 1995; Pasini et al., 1997; Iwashita
et al., 1999). To verify whether the resistance of V804
mutated RET kinases to pharmacological inhibition had
any impact on drug-induced reversion of the trans-
formed phenotype, we treated RAT1 ﬁbroblasts trans-
formed by RET/C634R, RET/M918T, RET/V804M or
RET/V804L with 5.0 mM ZD6474 for 24 h and analysed
the morphological changes induced by the drug. We
restricted this analysis to ZD6474 since it is already in
clinical trials (Wedge et al., 2002). Already at 1.0 mM,
ZD6474 caused a complete morphological reversion of
RET/C634R- and RET/M918T-transformed cells while
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it had very little effects on RET/V804M- and RET/
V804L-transformed cells (Figure 3).
To verify whether the resistance of V804 mutated
RET kinases to pharmacological inhibition was also
translated in the resistance of transformed cells to the
growth inhibitory properties of the compounds, we
measured ZD6474 effects on the growth rate of RAT1
ﬁbroblasts stably transformed by RET/C634R, RET/
V804M or RET/V804L. Growth curves reported in
Figure 4a demonstrate that ZD6474 strongly reduced
RAT1-RET/C634R cell growth, already at 1.0 mM,
while, at this dose, it had negligible effects on cells
expressing valine 804 mutants. Moreover, RET/C634R
cell growth was completely blocked by 5.0 mM of the
drug, while cells expressing valine 804 mutants were still
cycling although at a low rate. Overall, the effects of
V804 mutations on the resistance of the RET kinase to
the drugs appeared more dramatic than those on RET-
mediated mitogenic effects. Disagreement between anti-
proliferative effects in vivo and kinase inhibition in vitro
had been already described for other kinase inhibitors
and might be attributable to the different ATP
concentrations in the test tube and in intact cells or to
pleiotropic activity of the drug on multiple pathways in
living cells (Blencke et al., 2003).
Upon oncogenic activation, Grb2 recruitment to
tyrosine 1062 couples RET to the activation of the
Ras/mitogen-activated protein kinase (MAPK) cascade
(reviewed in Manie et al., 2001). To validate the results
showed above, as a read-out of RET mitogenic
signalling we analysed MAPK activation extent. In
particular, we measured the capability of ZD6474 to
obstruct RET-mediated activation of ERK1 and ERK2,
determined by immunoblot with phosphospeciﬁc anti-
bodies. Mutations of valine 804 resulted in a several-fold
reduction of RET signalling inhibition by ZD6474
(Figure 4b).
RET/V804G mutant sensitivity to PP1 and ZD6474
Valine 804 in RET corresponds to threonine 315 in
ABL, a residue that is located at a hydrophobic cavity
near the nucleotide binding site and that is implicated in
resistance to STI571 (Schindler et al., 2000; Gorre et al.,
2001; La Rosee et al., 2002; Nagar et al., 2002; Shah
et al., 2002) (Figure 5a). Furthermore, V804 in RET and
T315 in ABL correspond to T338 residue in SRC.
Mutation of this threonine to bulky residues decreased
SRC sensitivity to PP1, while substitution with a glycine
resulted in a sharp decrease of the IC50 (Bishop et al.,
Figure 1 (a) Schematic representation of the RET mutants used in this study. SP: signal peptide; EC: extracellular domain; IC:
intracellular domain; TM: transmembrane domain. (b and c) Protein extracts from HEK293 cells transiently transfected with the
indicated constructs and treated for 2 h with vehicle, PP1, PP2 or ZD6474 (0.5 or 5mM) were immunoblotted with phosphorylation-
speciﬁc anti-pY1062 RET antibodies. The results are representative of at least three independent assays
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2000). Thus, we reasoned that the steric indrance
determined by methionine or leucine in the two
spontaneous RET mutants (V804M or V804L) could
be the cause of RET resistance to both pyrazolopyr-
imidines and anilinoquinazolines. To prove this, we
substituted RET V804 with a glycine (the smallest
amino acid) in the context of a constitutively active
RET/C634R mutant. Initially, we tested if the V804G
mutation changed the enzymatic and/or transforming
activity of RET/C634R. Induction of transformed foci
in NIH3T3 ﬁbroblasts by RET/C634R-V804G was
slightly (two-fold) reduced in comparison to RET/
C634R (Figure 5b). Consistently, the kinase activity
of RET/C634R-V804G, at three different ATP con-
centrations (10, 100 and 500 mM), was mildly decreased
compared to RET/C634R (Figure 5c). This is consistent
with previous ﬁndings showing that, in other kinases,
the corresponding mutation modestly increased Km
for ATP (Bishop et al., 2000). Subsequently, HEK293
cells were transiently transfected with RET/C634R or
RET/C634R-V804G and treated with low doses (20,
50 or 100 nM) of PP1 or ZD6474 for 2 h. Protein
lysates were immunoblotted with anti-pY1062 antibody
to check RET phosphorylation levels in vivo. As
shown in Figure 5d, the RET/C634R-V804G mutant
was signiﬁcantly more sensitive to the two compounds
than wild-type RET/C634R. To obtain a quanti-
tative estimate of the effects of V804G mutation,
we measured ZD6474 IC50 of RET/C634R/V804G
by the in vitro poly-GT kinase assay. Consistent
with in vivo data, RET/C634R IC50 was decreased
by ﬁve-fold when valine 804 was changed to a glycine
(Figure 5e).
Figure 2 (a and b) In vitro poly-GT phosphorylation assay:
protein extracts were immunoprecipitated with anti-RET and
subjected to a kinase assay with poly-GT as a synthetic substrate,
[g-32P]ATP, and PP1 or ZD6474 at the indicated concentrations.
The phosphorylated poly-GT was spotted on 3MM Whatman
paper and counted by scintillation. The results of four independent
experiments were averaged and presented as residual poly-GT
phosphorylation levels compared with the control (DMSO).
Standard deviations are shown. (c) The IC50 of ZD6474 for
RET/C634R, RET/V804L or RET/V804M was measured by the
poly-GT phosphorylation assay, using decreasing amounts of
ZD6474 from 50.0 to 0.05mM. The results of four independent
experiments were averaged. Deviations were less than 20% of the
mean
Figure 3 The indicated cell lines were treated for 24 h with
DMSO, 1.0 or 5.0mM ZD6474. Cells were photographed by using a
phase-contrast light microscope (magniﬁcation  150)
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Discussion
Here we demonstrate that valine 804, mapping in the V
Hanks domain of the N-terminal lobe of the RET
kinase, is a structural determinant of sensitivity to
different classes of small molecule inhibitors. Thus, RET
resistance to enzymatic inhibition can be induced by
naturally occurring oncogenic mutations (V804L and
V804M), which change valine 804 to amino acids with
longer hydrophobic side chains like leucine or methio-
nine.
Our data integrate observations made on other
tyrosine kinases to demonstrate that one speciﬁc
position in several kinases is critical for kinase inhibition
by small molecular weight inhibitors. Indeed, in SRC
the nature of amino acid (position 338), corresponding
to RET V804, is crucial for sensitivity to PP1 and PP2.
SRC mutants that carry methionine or isoleucine in that
position are resistant to PP1 and PP2, while a glycine in
that position increases inhibition (Bishop et al., 2000).
The corresponding residue in the EGFR kinase (T766)
(Figure 5a) inﬂuences sensitivity to PD153035, a 4-
anilinoquinazoline like ZD6474 (Blencke et al., 2003).
Since ZD6474 has inhibitory properties also against
EGFR (Ciardiello et al., 2003), it is conceivable that
T766 EGFR mutants are resistant to ZD6474 as well.
Finally, the corresponding amino acid in ABL, threo-
nine 315, mediates sensitivity to STI571 (Schindler et al.,
2000; Gorre et al., 2001; La Rosee et al., 2002; Nagar
et al., 2002; Shah et al., 2002). Crystal structures have
shown that inhibitor moieties extend into a hydrophobic
cavity of the ATP-binding site that is not occupied by
the ATP itself. The residues mapping in position
corresponding to RET V804 lie in this cavity. Likely,
the presence of space-ﬁlling amino acids in that position
abrogates efﬁcient inhibitor binding. To formally prove
this possibility, we have inserted a glycine in position
804 of RET. The Val804Gly mutation strongly in-
creased RET sensitivity to PP1 and ZD6474.
A peculiar feature of the RET system described here is
that resistance-causing mutations are not selected during
treatment (like in the case of BCR-ABL). Rather they
are spontaneously occurring at the germline or somatic
level, in FMTC or sporadic MTC respectively, and
cause constitutive activation of RET and increased
signalling capacity (Pasini et al., 1997; Iwashita et al.,
Figure 4 (a) The indicated RAT1 cell lines stably expressing RET mutants were incubated with vehicle, 1.0 or 5.0mM ZD6474 and
counted at different time points. Day 1 was the treatment starting day. Data are the mean of two experiments performed in triplicate;
s.d. are indicated. (b) The indicated cell lines were serum starved for 24 h and then treated with vehicle or increasing concentrations
(1.0, 5.0, 20.0mM) of ZD6474 for 24 h. Cell lysates (100mg) were immunoblotted with anti-phosphoY1062 or phospho-MAPK. Anti-
RET and anti-MAPK antibody were used for normalization. These ﬁndings are representative of at least three independent
experiments
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1999). Therefore, V804M and V804L, at the same time,
activate the ligand-independent function of the RET
kinase and mediate resistance to inhibitory compounds.
This implies that in the case of RET resistance can also
pre-exist to the treatment. V804 mutations are found in
about 2% of MEN2 carriers as well as in sporadic
medullary thyroid carcinomas (Machens et al., 2003).
Familial cases have quite an aggressive potential and
several studies described a tendency of the tumor to
early onset and invasive behavior (Frohnauer and
Decker, 2000). In addition, V804 mutations can be
found in combination with other RET point-mutations
on different (Lombardo et al., 2002) or the same RET
allele. In particular, Bartsch et al. (2000) described an
FMTC kindred carrying a double RET mutation
(V804M and R844L), Kasprzak et al. (2001) reported
an FMTC family carrying the double V804M and V778I
mutation, Menko et al. (2002) described a MEN2B-like
family carrying a double V804M and S904C mutation
and Iwashita et al. (2000) described another MEN2B
family carrying a double V804M-Y806C mutation.
Intriguingly, this RET V804M-Y806C mutant exerted
an eight- to 13-fold higher transforming activity than
that of single RET mutants. Based on our ﬁndings, it
could be hypothesized that a second hit targeting V804
in an otherwise mutated RET allele could not only cause
potentiation of RET oncogenic activity but also
resistance formation.
In conclusion, our data support the notion that
human cancers sustaining oncogenic mutations of RET
may be treatable with pyrazolopyrimidines and
4-anilinoquinazolines. ZD6474 is currently under Phase
Figure 5 (a) Alignement of RET, ABL, EGFR and SRC sequences in the V Hanks domain. (b) NIH3T3 cells were transfected with
the indicated plasmids. Foci formation was scored after 2 weeks. (c) Protein lysates from marker-selected NIH3T3 cells stably
transfected with RET/C634R or RET/C634R-V804G were immunoprecipitated with anti-RET and subjected to an in vitro kinase
assay with poly-GT, [g-32P]ATP and different concentration of unlabelled ATP. The results of four independent experiments were
averaged. Standard deviations are shown. Expression levels of the RET constructs are shown in the immunoblot (50mg of total lysate)
reported in the inset. (d) Protein extracts from HEK293 cells transiently transfected with RET/C634R or RET/C634R-V804G
constructs and treated for 2 h with vehicle, PP1 or ZD6474 were immunoblotted with anti-pY1062 RET antibodies. (e) The IC50 of
ZD6474 for RET/C634R and RET/C634R-V804G was measured by the poly-GT phosphorylation assay. The results of four
independent experiments were averaged
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II clinical trial as an antiangiogenic compound. It is
envisaged that a clinical trial for MTC sustained by
RET mutations will be initiated soon. In the light of our
ﬁndings, V804 mutation positive tumors are expected to
display primary resistance to ZD6474. It is also
conceivable that the RET/V804 mutation could also
play a role in acquisition of secondary resistance, so
that, upon treatment, a tumor originally negative for the
mutation can select clones carrying the RET/V804
substitution and therefore no longer respond to the
therapy.
Materials and methods
Compounds
ZD6474 was kindly provided by AstraZeneca (Pharmaceuti-
cals, Macclesﬁeld, UK). PP1 and PP2 were purchased from
Alexis (San Diego, CA, USA). Stock solutions (50mM) were
made in 100% DMSO and diluted with culture media or
kinase buffer before use. Culture media or kinase buffer
containing an equivalent DMSO concentration served as
vehicle controls.
Cell culture
Mutations C634R, M918T, A883F, E768D, L790F, Y791F,
V804L, V804M and S891A were introduced in RET-9 cDNA,
encoding the short isoform of RET protein, cloned in the
pBABE expression vector (Pasini et al., 1997). The V804G
mutation was inserted by site-directed mutagenesis in the
pBABE RET/C634R construct (pBABE RET/C634R-
V804G). All the mutations were conﬁrmed by double-strand
DNA sequencing. HEK293 cells were from American Type
Culture Collection (ATCC, Manassas, VA, USA) and were
grown in Dulbecco’s Modiﬁed Eagle Medium (DMEM)
supplemented with 10% fetal calf serum (GIBCO, Paisley,
PA, USA). Transient transfections were carried out with the
lipofectamine reagent according to the manufacturer’s instruc-
tions (GIBCO). Cells were seeded at a density of 1.5 106/dish
the day before transfection, transfected with 5 mg of DNA and
harvested 48 h later. Parental RAT1 cells and RAT1 trans-
formed by RET/C634R, RET/V804L and RET/V804M were
cultured in DMEM supplemented with 10% fetal calf serum,
2mM L-glutamine and 100U/ml penicillin–streptomycin (GIB-
CO). NIH3T3 ﬁbroblasts were grown in DMEM (GIBCO)
containing 5% calf serum (GIBCO).
Immunoblotting
Protein lysates were prepared according to standard proce-
dures. Cells were lysed in a buffer containing 50mM N-2-
hydroxyethylpiperazine-N0-2-ethanesulfonic acid (HEPES; pH
7.5), 1% (vol/vol) Triton X-100, 150mM NaCl, 5mM EGTA,
50mM NaF, 20mM sodium pyrophosphate, 1mM sodium
vanadate, 2mM phenylmethylsulfonyl ﬂuoride (PMSF) and
1 mg/ml aprotinin. Lysates were clariﬁed by centrifugation at
10 000 g for 15min. Lysates containing comparable amounts
of proteins, estimated by a modiﬁed Bradford assay (Bio-Rad,
Munchen, Germany), were subjected to Western blot. Im-
munocomplexes were detected with the enhanced chemilumi-
nescence kit (Amersham Pharmacia Biotech, Little Chalfort,
UK). Anti-MAPK (#9101) and anti-phospho-MAPK (#9102)
were from New England Biolabs (Beverley, MA, USA). Anti-
RET is a polyclonal antibody raised against the tyrosine kinase
protein fragment of human RET (Santoro et al., 1995). Anti-
pY1062 and anti-pY905 are afﬁnity-puriﬁed polyclonal anti-
bodies raised against RET peptides containing phosphorylated
Y1062 or Y905 (Iwashita et al., 1996; Salvatore et al., 2000;
Carlomagno et al., 2003). Secondary antibodies coupled to
horseradish peroxidase were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA).
In vitro kinase assay
Subconﬂuent cells transfected with the different RET con-
structs were solubilized in lysis buffer with phosphatase and
protease inhibitors. An aliquot of 50mg of proteins was
immunoprecipitated with anti-RET antibodies; immunocom-
plexes were recovered with protein A sepharose beads, washed
ﬁve times with kinase buffer and incubated (20min at room
temperature) in kinase buffer containing 200 mM poly(L-
glutamic acid-L-tyrosine) (poly-GT) (Sigma-Aldrich Co, St
Louis, MO, USA), 2.5mCi [g-32P]ATP and unlabelled ATP to a
ﬁnal concentration of 20 mM in the presence of the inhibitory
compound or vehicle. Samples were spotted on Whatman
3MM paper (Springﬁeld Mill, UK) and 32P incorporation was
measured with a b-counter scintillator (Beckman Coulter,
Unterschleissheim-Lohhof, Germany).
Growth curves and transformation assay
RAT1 cells (1 104/dish) were seeded on 60-mm dishes in
complete medium. The day after (day 1), compounds or vehicle
were added to the medium and refreshed every 2 days. Cells
were counted every 2 days. For transformation assay, 1 105
NIH3T3 ﬁbroblasts were seeded in 10mm dishes. The day
after cells were transfected using the calcium-phosphate
precipitation method, as described elsewhere (Santoro et al.,
1995). Transformed foci were scored at 2 weeks. Transforming
efﬁciency was calculated in focus forming units (FFUs) per
pmol of added DNA after normalization for the efﬁciency of
colony formation in parallel dishes subjected to marker
selection.
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 BAY 43-9006 Inhibition of Oncogenic RET Mutants 
 Francesca  Carlomagno ,  Suresh  Anaganti ,  Teresa  Guida ,  Giuliana  Salvatore , 
 Giancarlo  Troncone ,  Scott M.  Wilhelm ,  Massimo  Santoro 
 Background : Medullary and papillary thyroid carcinomas 
are often associated with oncogenic activation of the RET 
tyrosine kinase. We evaluated whether the biaryl urea BAY 
43-9006, which is known to inhibit several other tyrosine 
kinases, blocks RET kinase function and oncogenic activity. 
 Methods : We examined BAY 43-9006 activity against onco-
genic RET in vitro and in cellular RET signaling in oncogenic 
RET-transfected NIH3T3 fi broblasts by using immunocom-
plex kinase assays and immunoblotting with phospho-specifi c 
antibodies. The effects of BAY 43-9006 on proliferation of 
human TPC1 and TT thyroid carcinoma cells, which harbor 
spontaneous oncogenic RET alleles, and on RAT1 fi broblasts 
transformed with oncogenic RET mutants, including mutants 
that are resistant to other chemotherapeutic agents, were 
determined using growth curves and fl ow cytometry. Growth 
of TT cell – derived xenograft tumors in athymic mice treated 
orally with BAY 43-9006 or with vehicle was measured. All 
statistical tests were two-sided.  Results : BAY 43-9006 inhib-
ited oncogenic RET kinase activity at half-maximal inhibi-
tory concentrations (IC  50  s) of 50 nM or less in NIH3T3 cells. 
It also arrested the growth of NIH3T3 and RAT1 fi broblasts 
transformed by oncogenic RET and of thyroid carcinoma 
cells that harbor spontaneous oncogenic RET alleles. More-
over, BAY 43-9006 inhibited the growth of cells carrying RET 
V804L (IC  50  = 110 nM, 95% confi dence interval [CI] = 88 to 
133 nM) or RET V804M (IC  50  = 147 nM, 95% CI = 123 nM 
to 170 nM), both mutants that are resistant to anilinoquin-
azolines and pyrazolopyrimidines. After 3 weeks of oral 
treatment with BAY 43-9006 (60 mg/kg/day), the volume of 
TT cell xenografts ( n = 7) was reduced from 72.5 to 44 mm  3  
(difference = 28.5 mm  3  , 95% CI = 7 mm  3  to 50 mm  3  ), whereas 
in vehicle-treated mice ( n = 7), mean tumor volume increased 
to 408 mm  3  (difference = 320 mm  3  , 95% CI = 180 mm  3  to 460 
mm  3  ; untreated versus treated,  P =.02). This inhibition paral-
leled a decrease in RET phosphorylation.  Conclusions : BAY 
43-9006 is a powerful inhibitor of the RET kinase. Its poten-
tial as a therapeutic tool for RET-positive thyroid tumors, 
including those expressing V804 mutations merits study. 
 [J Natl Cancer Inst 2006;98:326 – 34] 
 RET is a single-pass transmembrane tyrosine kinase receptor 
and is part of a cell-surface complex that binds growth factors of 
the glial-derived neurotrophic factor (GDNF) family in associa-
tion with four different coreceptors, GFR α 1 – 4  ( 1 ) . The RET 
gene is a potent oncogene that is involved in the pathogenesis of 
several human tumors. In papillary thyroid carcinoma  ( 2 ) , chro-
mosomal inversions or translocations cause the in-frame fusion 
of the tyrosine kinase-encoding domain of RET with the 5 ′ -end 
of heterologous genes. The resulting RET/papillary thyroid car-
cinoma (PTC) chimeric sequences are oncogenic. The most 
frequent rearrangements are RET/PTC1 and RET/PTC3 formed 
by the fusion with the H4/D10S170 or the RFG/ELE1genes, 
 respectively  ( 1 ) . Virtually all of the translocated amino termini 
that have been found to be fused to RET are predicted to fold 
into coiled coils. These motifs provide RET/PTC kinases with 
the ability to undergo ligand-independent dimerization and 
 allow constitutive activation of RET. Moreover, the promoters 
of the fused gene drive the expression of the rearranged RET 
alleles  ( 1 ) . 
 Germline point mutations in RET cause the dominantly in-
herited multiple endocrine neoplasia (MEN) type 2A and 2B and 
familial medullary thyroid carcinoma. MEN 2 patients are af-
fected by medullary thyroid carcinoma, a malignant tumor that 
arises from calcitonin-secreting C cells. Familial medullary thy-
roid carcinoma predisposes patients to medullary thyroid carci-
noma alone, whereas other features can be associated with MEN 
2A (pheochromocytoma, parathyroid hyperplasia, and heredi-
tary localized pruritus) and MEN 2B (pheochromocytoma, gan-
glioneuromatosis of the intestine, thickening of corneal nerves, 
and marfanoid habitus)  ( 3 – 5 ) . Most MEN 2B patients carry the 
M918T mutation in the RET kinase domain, and only a small 
fraction harbor the A883F substitution  ( 4 , 5 ) . Most MEN 2A and 
familial medullary thyroid carcinoma patients carry mutations 
that affect a cysteine residue in the extracellular cysteine-rich 
domain of RET (most often C634). Familial medullary thyroid 
carcinoma is also associated with changes in the N-terminal 
(E768D, L790F, Y791F, V804L, and V804M) or C-terminal 
(S891A) regions of the RET kinase  ( 3 – 5 ) . Point substitutions 
at V804, M918, and E768 are found in approximately 30% of 
patients with sporadic medullary thyroid carcinoma  ( 3 – 5 ) . The 
mechanisms that lead to RET oncogenic conversion in MEN 2 
depend on the location of the amino acid change. Extracellular 
cysteine mutants display constitutive kinase activity after ho-
modimerization. Constitutive activation and altered substrate 
specifi city have been implicated in the case of RET intracellular 
domain mutations  ( 1 ) . 
 Although RET kinase is constitutively active in both papil-
lary thyroid carcinoma and medullary thyroid carcinoma, the 
diseases are physiologically different. Local disease control by 
surgical resection, adjuvant radioiodine treatment, and thyroid 
hormone replacement are the cornerstones of treatment for pap-
illary thyroid carcinoma  ( 2 ) . However, if this treatment fails, 
patients may succumb to the disease  ( 6 ) . Early diagnosis and 
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treatment are  essential for the survival of patients with medul-
lary thyroid carcinoma, because the disease does not respond to 
standard chemotherapy or to conventional radiotherapy. Unfor-
tunately, medullary thyroid carcinoma is often incurable be-
cause the cancer has  metastasized to regional lymph nodes or 
distant sites before diagnosis. Thus, for many patients with he-
reditary or sporadic medullary thyroid carcinoma and for some 
patients with papillary thyroid carcinoma, there is no effective 
treatment  ( 6 ) . 
 Protein kinases have become one of the most important tar-
gets for anticancer drug development. The approval of  imatinib 
(Gleevec) for chronic myeloid leukemia and gefi tinib (Iressa) 
and erlotinib (Tarceva) for non – small-cell lung cancer has pro-
vided proof of the principle of the effectiveness of small- molecule 
kinase inhibitors  ( 7 ) . The causative role played by RET germline 
mutations in familial medullary thyroid carcinoma  ( 3 – 5 ) , the 
presence of RET alterations in very early phases of papillary 
 thyroid carcinoma and medullary thyroid carcinoma  ( 8 ), and the 
ability of RET oncogenes to initiate tumor formation in tissue-
specifi c transgenic animals  ( 8 ) make RET a prime target for 
 thyroid cancer therapies. Small molecules of various chemical 
classes have been reported to inhibit RET; these include two 
pyrazolopyrimidines (PP1 and PP2)  ( 9 – 11 ) , the 2- indolinone 
RPI-1  ( 12 ) , two indolocarbazole derivatives (CEP-701 and CEP-
751)  ( 13 ) , and the anilinoquinazoline ZD6474, which is in an 
advanced phase of clinical study  ( 14 , 15 ) . A methionine or leucine 
substitution for valine 804 (V804M and V804L) in RET confers 
resistance to ZD6474, PP1, and PP2  ( 16 ) . V804 mutations are 
present alone or with other RET  mutations in MEN 2 carriers 
(approximately 4% of patients) and in sporadic medullary thy-
roid carcinoma patients  ( 4 , 17 – 23 ) . V804 in RET corresponds 
to residues in ABL (T315)  ( 24 ) ,  epidermal growth factor recep-
tor (EGFR) (T790)  ( 25 , 26 ) , KIT (T670)  ( 27 ), and platelet- derived 
growth factor receptor A (PDGFRA) (T674)  ( 28 ), whose mu-
tation mediates resistance to inhibitors of various chemical 
classes. 
 BAY 43-9006 is a biaryl urea that targets the serine/threonine 
kinases RAF-1 and BRAF  ( 29 , 30 ) and the tyrosine kinase recep-
tors VEGFR-2 (KDR), VEGFR-3 (Flt-4), Flt-3, PDGFR-B, and 
KIT  ( 30 ) . BAY 43-9006 is an orally available cytostatic agent that 
is undergoing advanced clinical trials  ( 30 ) . In this study, we ex-
ploit the ability of BAY 43-9006 to inhibit RET activity/signaling 
and the autonomous growth and tumorigenicity of human cell 
lines carrying oncogenic RET alleles. 
 M ATERIALS AND M ETHODS 
 Compounds 
 BAY 43-9006,  N -(3-trifl uoromethyl-4-chlorophenyl)- N ′ -(4-
[2-methylcarbamoyl pyridin-4-yl]oxyphenyl) urea, was provided 
by Bayer HealthCare Pharmaceuticals (West Haven, CT). PP1, 
4-amino-5-(4-methylphenyl)-7-( t -butyl)pyrazolo[3,4-d]-pyrimi-
dine, was purchased from Alexis (San Diego, CA). For in vitro 
experiments, BAY 43-9006 and PP1 were dissolved in dimethyl 
sulfoxide. For in vivo experiments, BAY 43-9006 was dissolved 
in Cremophor EL – ethanol (50 : 50 Sigma Cremophor EL – 95% 
ethyl alcohol) (Sigma Chemical Co., St. Louis, MO) at fourfold 
(4×) the highest dose, foil-wrapped, and stored at room tempera-
ture. The 4× stock solution was prepared fresh every 3 days. The 
fi nal dosing solution was prepared on the day of use by dilution 
of the stock solution to 1× with water. 
 Immunoblotting Analysis 
 Protein lysates were prepared according to standard proce-
dures. Briefl y, mouse fi broblasts and human thyroid carcinoma 
cells or snap-frozen tumor samples were lysed in a buffer 
 containing 50 mM HEPES (pH 7.5), 1% (vol/vol) Triton X-100, 
150 mM NaCl, 5 mM EGTA, 50 mM NaF, 20 mM sodium pyro-
phosphate, 1 mM sodium vanadate, 2 mM phenylmethylsulfo-
nyl fl uoride, and aprotinin at 1  μ g/mL. Lysates were clarifi ed by 
 centrifugation at 10 000 × g for 15 minutes. Lysates containing 
com parable amounts of proteins, as estimated by a modifi ed 
Bradford assay (Bio-Rad, Munich, Germany)  ( 31 ) , were sub-
jected to direct Western blotting. Immune complexes were de-
tected with the enhanced chemiluminescence kit (Amersham 
Pharmacia Biotech, Little Chalfort, UK). Signal intensity was 
analyzed using a PhosphorImager (Typhoon 8600, Amersham 
Pharmacia Biotech) interfaced with the ImageQuant software. 
Anti- phospho-Shc (1 : 1000), which recognizes phosphorylated 
Shc at Y317, was a rabbit polyclonal antibody from Upstate 
 Biotechnology, Inc. (Lake Placid, NY). Anti-Shc (1 : 1000) was 
a rabbit polyclonal antibody from Santa Cruz Biotechnology 
(Santa Cruz, CA). Anti-mitogen-activated protein kinase 
(MAPK) (1 : 1000) and anti-phospho-MAPK (1 : 1000), which 
recognizes p44/42MAPK (ERK1/2) phosphorylated at Thr202/
Tyr204, were rabbit polyclonal antibodies from Cell Signaling 
(Beverly, MA). Anti-RET (1 : 1000) is a rabbit polyclonal anti-
body raised against the  tyrosine kinase protein fragment of hu-
man RET  ( 32 ) . Anti-phospho905 is a phospho-specifi c polyclonal 
antibody that recognizes RET proteins that are phosphorylated 
at Y905  ( 10 ) . Blots were incubated with primary antibodies for 
1 hour at room temperature, followed by three washes in buffer 
(20 mM Tris-HCl at pH 7.5, 150 mM NaCl, and 0.05% Tween 
20). The blots were then incubated with the goat anti-rabbit sec-
ondary antibody (1 : 5000) coupled to horseradish peroxidase 
(Santa Cruz Biotechnology) for 1 hour at room temperature 
 followed by three washes in buffer (20 mM Tris-HCl at pH 7.5, 
150 mM NaCl, and 0.05% Tween 20). Each experiment was 
 performed at least three times. 
 Cell Culture 
 Parental murine NIH3T3 fi broblasts and NIH3T3 cells stably 
transfected with the RET mutants RET/PTC3, RET/C634R 
(MEN 2A), and RET/M918T (MEN 2B), the EGFR/RET chime-
ric receptor (the extracellular and transmembrane portions of 
the EGFR fused to the intracellular domain of RET), and GFR α 1 
(GDNF receptor  α 1) plus wild-type RET are described else-
where  ( 14 , 32 ). Cells were cultured in Dulbecco’s modifi ed 
 Eagle’s  medium (DMEM) supplemented with 5% calf serum, 
2 mM  L -glutamine, and penicillin-streptomycin at 100 units/mL 
(GIBCO, Paisley, PA). Epidermal growth factor (EGF) was pur-
chased from Upstate Ltd. (Charlottesville, VA); GDNF was pur-
chased from Alomone Labs (Jerusalem, Israel). The TPC1 cell 
line, derived from a papillary thyroid carcinoma harboring the 
RET/PTC1 rearrangement  ( 33 ) , was cultured in DMEM with 
10% fetal calf serum, 2 mM  L -glutamine, and  penicillin-
 streptomycin at 100 units/mL. The TT cell line, derived from a 
 medullary thyroid carcinoma (MTC) harboring the RET/C634W 
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mutation  ( 34 ) , was cultured in RPMI-1640 with 20% fetal 
calf serum, 2 mM  L -glutamine, and 100 units/mL penicillin-
streptomycin (GIBCO). Parental Fischer rat – derived RAT1 
 fi broblasts and RAT1 transformed by RET/C634R, RET/V804L, 
or RET/V804M are described elsewhere  ( 35 ) and were cultured 
in DMEM with 10% fetal calf serum, 2 mM  L -glutamine, and 
100 units/mL penicillin-streptomycin (GIBCO). All RET con-
structs used in this study encoded the short isoform of the RET 
protein (RET-9)  ( 1 ) . 
 In Vitro Kinase Assays 
 For the in vitro RET autophosphorylation assay, subconfl u-
ent NIH3T3 cells stably transfected with RET/PTC3 were solu-
bilized in lysis buffer without phosphatase inhibitors (sodium 
 fl uoride, sodium pyrophosphate, and sodium vanadate). Then, 
200  μ g of proteins were immunoprecipitated with anti-RET; 
 immunocomplexes were recovered with protein A – Sepharose 
beads, washed fi ve times with kinase buffer (20 mM HEPES 
at pH 7.5, 150 mM NaCl, 10% glycerol, 0.1% Triton X-100, 
15 mM MnCl 2 , and 15 mM MgCl 2 ) and incubated 20 minutes 
at room temperature in kinase buffer containing 2.5  μ Ci of 
[ γ - 32 P]ATP and unlabeled ATP (20  μ M)  ( 9 ) . Samples were 
 separated by 10%  sodium dodecyl sulfate – polyacrylamide gel 
electrophoresis. Gels were dried and exposed to fi lm for autora-
diography. Signal intensity was analyzed using a PhosphorIm-
ager (Typhoon 8600) interfaced with the ImageQuant software. 
For phosphorylation of the synthetic substrate, RET immuno-
complexes were incubated (20 minutes at room temperature) 
in kinase buffer containing 200  μ M poly-( L -glutamic acid- L -
 tyrosine [poly-GT]) (Sigma), 2.5  μ Ci of [ γ - 32 P]ATP, and unla-
beled ATP (20  μ M). Samples were spotted on Whatman 3MM 
paper (Springfi eld Mill, UK), and  32 P incorporation was 
 measured with a beta counter scintillator (Beckman Coulter, 
Unterschleissheim-Lohhof, Germany). Each experiment was 
performed at least three times. 
 Growth Curves and Cell Cycle Analysis 
 NIH3T3 (10  000/dish) and RAT1 fi broblasts (10  000/dish) and 
human thyroid carcinoma TPC1 (35  000/dish) and TT (90  000/
dish) cells were seeded in 60-mm dishes. Fibroblasts were main-
tained in medium supplemented with 1% calf (NIH3T3) or fetal 
calf (RAT1) serum. Human cells were maintained in 2% (TPC1) 
or 10% (TT) fetal calf serum. The next day, BAY 43-9006 or ve-
hicle was added to the medium and changed every 2 days. Cells 
were counted every 2 (fi broblasts) or 2 – 3 (human cell lines) days. 
For fl ow cytometry analysis, cells were grown to subconfl uence 
in 100-mm dishes and then treated with vehicle or 1.0  μ M BAY 
43-9006 for 24 hours. After harvesting, cells were fi xed in cold 
70% ethanol in phosphate-buffered saline. Cells were washed 
and resuspended in phosphate-buffered saline. Propidium iodide 
(25  μ g/mL) was added, and samples were analyzed with a 
FACSCalibur fl ow cytometer (Becton Dickinson, San Jose, CA) 
interfaced with a Hewlett Packard computer (Palo Alto, CA). 
 Experiments were performed three times in duplicate. 
 Tumor Growth in Athymic Mice 
 Mice ( n = 14) were housed in barrier facilities that provided 
12-hour light-dark cycles and received food and water ad  libitum 
at the Dipartimento di Biologia e Patologia Cellulare e Moleco-
lare (University of Naples  “ Federico II, ” Naples, Italy). This 
study was conducted in accordance with Italian regulations for 
experimentation on animals. All manipulations were performed 
while mice were under isofl urane gas anesthesia. No mouse 
showed signs of wasting or other signs of toxicity. TT cells 
(1 × 10 7 /mouse) were inoculated subcutaneously into the right 
 dorsal portion of 4-week-old male BALB/c  nu/nu mice (The 
Jackson Laboratory, Bar Harbor, ME). When tumors measured 
 ~ 70 mm 3 , after approximately 30 days, mice were randomized 
to receive BAY 43-9006 ( n = 7, 60 mg/kg/day) or vehicle ( n = 
7, Cremophor EL – ethanol) alone by oral gavage for 5 consecu-
tive days/week for 3 weeks. Tumor diameters were measured at 
 regular intervals with calipers. Tumor volumes (V) were calcu-
lated with the formula: V = A × B 2 /2 (A = axial diameter; B = 
rotational diameter). Mice were killed by cervical dislocation, 
and tumors were excised and divided in two parts. Half of 
the tissue was snap-frozen in liquid nitrogen and used for pro-
tein extraction. The other half was fi xed overnight in neutral 
 Fig. 1.  In vitro inhibition of RET/papillary thyroid carcinoma (PTC) 3 by BAY 
43-9006.  A ) In vitro RET autophosphorylation assay. Protein extracts from NIH-
RET/PTC3 cells were immunoprecipitated with rabbit polyclonal anti-RET 
antibody and subjected to an immunocomplex kinase assay in the presence of 
[ γ - 32 P]ATP. BAY 43-9006 or vehicle alone (dimethyl sulfoxide [DMSO]) was 
added to the reaction mixture to reach the indicated concentrations. Reaction 
products were separated by 10% sodium dodecyl sulfate – polyacrylamide gel 
electrophoresis, and phosphorylated proteins were detected by autoradiography 
and quantifi ed using a PhosphorImager. A representative blot from three 
independent experiments is shown. Aliquots of the immunoprecipitates were 
subjected to anti-RET Western blot for normalization (data not shown).  B ) In 
vitro poly-GT phosphorylation assay. Protein extracts from NIH-RET/PTC3 cells 
were immunoprecipitated with the anti-RET antibody and subjected to a kinase 
assay with poly-( L -glutamic acid- L -tyrosine (poly-GT) as a synthetic substrate in 
the presence of [ γ - 32 P]ATP and different concentrations of vehicle or BAY 43-
9006. The phosphorylated poly-GT was spotted on fi lter paper, and radioactivity 
was counted by scintillation. The results are reported as residual poly-GT 
phosphorylation levels compared with the control (DMSO). The concentration 
of drug that inhibited activity by 50% (IC 50 ) is shown. Each  point represents the 
mean value from four independent determinations;  error bars represent 95% 
confi dence intervals. 
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buffered formalin and processed by routine methods. Paraffi n-
 embedded blocks were sliced into 5- μ m sections and stained by 
hematoxylin and eosin for histologic examination or processed 
for immunohistochemistry. 
 Statistical Analysis 
 Kinase activity curves were graphed using the curve-fi tting 
PRISM software (GraphPad Software). To compare cell growth 
we used the unpaired Student’s  t test (normal distributions and 
equal variances) and the JMP software program (version 5.1.1; 
SAS Institute, Inc, Austin, TX). To compare tumor growth we 
used the paired Student’s  t test (normal distributions and equal 
variances) and the JMP software program (version 5.1.1; SAS 
 Institute), an analysis of variance (linear mixed-effect model) test 
for repeated measures and the Wilcoxon’s rank-sum test and the 
Instat software program (GraphPad Software). All  P values were 
two-sided, and differences were statistically signifi cant at  P <.02. 
 R ESULTS 
 BAY 43-9006 Effects on Oncogenic RET 
Autophosphorylation In Vitro 
 Oncogenic RET proteins undergo autophosphorylation in  vitro 
in the absence of ligand  ( 32 ) . We used an in vitro autophos-
phorylation assay to determine whether BAY 43-9006 inhibited 
the autophosphorylation of RET/PTC3 (i.e., oncogenic variant) 
kinase immunopurifi ed from stably transfected NIH3T3 cells. 
BAY 43-9006 inhibited RET/PTC3 autophosphorylation with an 
IC 50 of roughly 50 nM (Fig 1, A). We performed a second in vitro 
enzymatic assay to measure the ability of RET/PTC3 to phosphor-
ylate a synthetic poly-GT substrate. BAY 43-9006 blocked this 
activity of RET/PTC3 with an IC 50 of 47 nM (95% CI = 34 nM 
to 61 nM) ( Fig. 1 , B). 
 Inhibition of RET Signaling and Cell Proliferation in 
RET-Transformed Cells by BAY 43-9006 
 We next determined whether BAY 43-9006 could also in-
hibit the kinase activity of oncogenic RET mutants in intact 
cells. We treated NIH3T3 fi broblasts expressing one of three 
oncogenic versions of RET (RET/PTC3, RET/C634R, or RET/
M918T) with BAY 43-9006 for 2 hours. We then measured RET 
phosphorylation levels by immunoblotting with an antibody 
that recognizes RET only when it is phosphorylated at tyrosine 
905 (Y905)  ( 10 , 36 ) . Treatment with BAY 43-9006 reduced 
the phosphotyrosine content of RET/PTC3, RET/C634R, and 
RET/M918T with an IC 50 of 20 – 50 nM ( Fig. 2, B – D ). The three 
RET kinases were almost completely inhibited by 100 nM 
BAY 43-9006 ( Fig. 2, B – D ). We used two cell systems to test 
whether BAY 43-9006 could also inhibit wild-type RET: 
NIH3T3 fi broblasts that express the EGFR/RET chimera (in 
which the RET kinase can be stimulated by EGF) and those that 
coexpress wild-type RET and GFR α 1 (in which the RET kinase 
can be stimulated by GDNF) ( Fig. 2 , A). BAY 43-9006 inhib-
ited  autophosphorylation of both EGFR/RET and wild-type 
RET ( Fig. 2, E – F ). 
 Fig. 2. In vivo inhibition of phosphorylation of 
wild-type RET and of RET/papillary thyroid 
carcinoma (PTC) 3, RET/C634R, RET/M918T, 
and epidermal growth factor receptor (EGFR)/RET 
by BAY 43-9006 in transfected NIH 3T3 cells.  A ) 
Schematic representation of the various constructs. 
EC = extracellular domain; IC = intracellular domain; 
TM = transmembrane domain.  B – F ) Serum-starved 
cells (24 hours) were treated with vehicle (dimethyl 
sulfoxide [DMSO]) or different concentrations of 
BAY 43-9006 for 2 hours; before harvesting, EGFR/
RET and glial-derived neurotrophic factor (GDNF) 
family receptor  α 1 (GFR α 1) + RET expressing 
cells were treated for 10 minutes with 100 ng/mL 
of epidermal growth factor (EGF) or GDNF, re-
spectively. Cell lysates (50  μ g) were immunoblotted 
with a rabbit polyclonal anti-phospho-RET/Y905 
( α pY905) antibody to detect phosphorylation and 
with anti-RET ( α RET) as a control for protein 
loading and transfer. The signal was quantifi ed using 
a PhosphorImager. Representative blots from three 
independent experiments are shown. 
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 Constitutively active oncogenic versions of RET activate the 
RAS/RAF/MAPK pathway by recruiting Grb2/Sos complexes 
through the Shc protein  ( 1 , 37 ) . Accordingly, we treated RET/PTC3 
cells with increasing concentrations of BAY 43-9006 and analyzed 
Shc and p44/p42MAPK phosphorylation by immunoblotting with 
phospho-specifi c antibodies. BAY 43-9006 inhibited RET/PTC3-
dependent phosphorylation of Shc and p44/42MAPK with an IC 50 
of approximately 50 nM ( Fig. 3 , A). Similar results were obtained 
with RET/C634R and RET/M918T mutants (not shown). 
 We studied the effects exerted by BAY 43-9006 on the growth 
of NIH3T3 cells transformed by RET/PTC3, RET/C634R, and 
RET/M918T that were grown in low serum (2.5%) for 10 days. 
Proliferation of NIH3T3 cells transformed with any of these RET 
mutants was virtually arrested after treatment with 1  μ M of BAY 
43-9006 ( Fig. 3 , B). Fewer RET/PTC3 cells remained after treat-
ment with 1  μ M of BAY 43-9006 than after treatment with vehi-
cle (8.4  × 10 3 , 95% CI = 7.2  × 10 3 to 9.6  × 10 3 versus 730.5  × 
10 3 , 95% CI = 684  × 10 3 to 776  × 10 3 ;  P <.001). Results were 
similar for RET/C634R and RET/M918T cells after treatment 
with 1  μ M of BAY 43-9006 or with vehicle (RET/C634R cells, 
8.1  × 10 3 , 95% CI = 6.7  × 10 3 to 9.6  × 10 3 , versus 552  × 10 3 , 95% 
CI = 509  × 10 3 to 594 × 10 3 ;  P <.001; and RET/M918T cells, 
11  × 10 3 , 95% CI = 7.9  × 10 3 to 14  × 10 3 , versus 612 x 10 3 , 95% 
CI = 591  × 10 3 to 634  × 10 3  P <.001). Hence, BAY 43-9006 
 antagonized RET oncogenic activity by blocking its kinase func-
tion and its signaling and mitogenic effects. 
 Effects of BAY 43-9006 on Human Carcinoma Cells 
Harboring a Constitutively Active RET Oncogene 
 We next investigated the effects of BAY 43-9006 on the TPC1 
cell line, which is derived from a human PTC bearing the RET/
PTC1 rearrangement  ( 33 ), and the TT cell line, which is derived 
from a human MTC harboring the RET/C634W mutation  ( 34 ) . 
Treatment of either cell line with 100 nM BAY 43-9006 almost 
completely abrogated RET and Shc phosphorylation ( Fig. 4 , A 
and B). This treatment abrogated p44/p42 MAPK phosphoryla-
tion in TT cells and strongly reduced it (by approximately 50%) 
in TPC1 cells ( Fig. 4 , A and B). 
 We next measured the growth rates of TPC1 (grown in 2% 
serum) and TT (grown in 10% serum) cells treated with three 
concentrations of BAY 43-9006 ( Fig. 4 , C). Fewer TPC1 cells 
remained after treatment for 6 days with 1000 nM BAY 43-9006 
than with vehicle (21  × 10 3 , 95% CI = 17  × 10 3 to 24  × 10 3 , 
 versus 135  × 10 3 , 95% CI = 127  × 10 3 to 143  × 10 3 ;  P <.001). The 
number of TPC1 cells remaining after 6 days of treatment with 
250 nM BAY 43-9006 was lower than that of cells treated with 
vehicle (65  × 10 3 , 95% CI = 59  × 10 3 to 71  × 10 3 , versus 135  × 10 3 , 
95% CI = 127  × 10 3 to 143  × 10 3 ;  P <.001). A reduction of TPC1 
growth was still observed at a 100 nM dose (116  × 10 3 , 95% 
CI = 107  × 10 3 to 125  × 10 3 , versus 135  × 10 3 , 95% CI = 127  × 10 3 
to 143  × 10 3 ;  P <.001). Fewer TT cells remained after 10 days 
of treatment with 1000 nM BAY 43-9006 than with  vehicle 
 Fig. 3. Inhibition of RET-mediated growth and signaling by BAY 43-9006.  A ) 
NIH3T3 cells transfected with RET/papillary thyroid carcinoma (PTC) 3 were serum-
starved for 24 hours and then treated with vehicle (dimethyl sulfoxide [DMSO]) or 
increasing concentrations of BAY 43-9006. Cell lysates (50  μ g) were immunoblotted 
with rabbit polyclonal anti-phospho-specifi c Shc or p44/42 mitogen-activated 
protein kinase (MAPK) antibodies and with anti-MAPK antibody as a control for 
protein loading and transfer. The signal was analyzed using a PhosphorImager. A 
representative blot from three independent experiments is shown.  B ) The indicated 
cell lines were incubated with DMSO or 1.0  μ M BAY 43-9006 in 1% calf serum, 
and the cells were counted at different time points. Each  point represents the mean 
value for fi ve dishes, and  error bars represent 95% confi dence intervals.  P values 
were determined by the two-tailed unpaired Student’s  t test. * P <.001. 
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(109  × 10 3 , 95% CI = 100  × 10 3 to 118  × 10 3 , versus 541  × 10 3 , 95% 
CI = 487  × 10 3 to 584  × 10 3 ;  P <.001). The number of TT cells 
remaining after 10 days of treatment with 250 nM BAY 43-9006 
was lower than that after treatment with vehicle (199 × 10 3 , 
95% CI = 187  × 10 3 to 211  × 10 3 , versus 541  × 10 3 , 95% CI = 
487  × 10 3 to 584  × 10 3 ;  P <.001). We also observed growth inhi-
bition at 100 nM BAY 43-9006 (309  × 10 3 , 95% CI = 285  × 10 3 
to 332  × 10 3 , versus 541  × 10 3 , 95% CI = 487  × 10 3 to 584  × 10 3 ; 
 P <.001). 
 Examination of the TT and TPC1 cell cycle profi les by fl ow 
cytometry showed a marked G 1 arrest of both cell lines upon 
treatment with 1  μ M BAY 43-9006 ( Fig. 4 , D). There were ap-
proximately 10-fold more TPC1 cells in the sub-G 1 fraction after 
BAY 43-9006 treatment compared with vehicle treatment. 
In  addition to its cytostatic effect, BAY 43-9006 exerts a pro-
apoptotic effect at this drug concentration. Thus, BAY 43-9006 
blocks oncogenic RET signaling in TT and TPC1 cells and has a 
mainly cytostatic effect. 
 Inhibition of RET/V804 Mutants by BAY 43-9006 
 Mutations of valine 804 in RET to leucine (V804L) or methio-
nine (V804M) ( Fig. 5 , A) render RET resistant (approximately 
50-fold increase of the IC 50 ) to the small-molecule tyrosine 
 kinase/RET inhibitors PP1, PP2, and ZD6474  ( 16 ) . We measured 
the effect of BAY 43-9006 on the activity of RET/V804L and 
RET/V804M kinases using the in vitro poly-GT kinase assay. 
Despite their resistance to other inhibitors, both mutants were 
only two- to threefold less sensitive than RET/C634R to inhibi-
tion by BAY 43-9006. The IC 50 of BAY 43-9006 was 110 nM for 
RET/V804L (95% CI = 88 nM to 133 nM) and 147 nM for RET/
V804M (95% CI = 123 nM to 170 nM), whereas the IC 50 of BAY 
43-9006 for RET/C634R was 49 nM (95% CI = 35 nM to 62 nM) 
( Fig. 5 , B). 
 We sought to verify these fi ndings in intact cells. RAT1 fi bro-
blasts expressing the RET/V804L or the RET/V804M alleles were 
treated for 2 hours with vehicle, BAY 43-9006, or PP1 (500 or 
1000 nM), and RET phosphorylation was measured by immuno-
blotting. Similar to the in vitro data, only residual phosphorylation 
of the two mutant proteins (more pronounced for V804M) was 
detected after treatment with 500 nM BAY 43-9006 ( Fig. 5 , C). 
Mutant RET phosphorylation was virtually abrogated by 1000 nM 
BAY 43-9006 ( Fig. 5 , C). As previously reported  ( 16 ) , PP1 only 
slightly inhibited RET phosphorylation at these doses ( Fig. 5 , C). 
 We studied the effects exerted by BAY 43-9006 on the growth 
rate of RAT1 cells transformed by RET/V804M and RET/C634R 
( Fig. 5 , D). Fewer RET/C634R cells remained after 9 days of 
treatment with 0.1  μ M BAY 43-9006 than with vehicle (46  × 10 4 , 
 Fig. 4. Inhibition of RET-mediated growth and signaling by BAY 43-9006 in 
human cells. TPC1 ( A ) and TT ( B ) cell lines were serum-starved for 24 hours 
and then treated with vehicle or BAY 43-9006. Cell lysates (50  μ g) were 
immunoblotted with rabbit polyclonal anti-phospho-RET, phospho-Shc, phospho-
mitogen-activated protein kinase (MAPK), and MAPK antibodies as a control 
for protein loading and transfer. Representative blots from three independent 
experiments are shown.  C ) TPC1 and TT cells were incubated with vehicle, 100, 
250, or 1000 nM BAY 43-9006 in 10% and 2% serum, respectively, and counted 
at different time points. Each  point represents the mean value for fi ve dishes and 
 error bars represent 95% confi dence intervals.  P values were determined using 
the two-tailed unpaired Student’s  t test. * P <.002.  D ) After 24 hours of serum 
starvation, TPC1 and TT cells were treated with vehicle or with 1.0  μ M BAY 
43-9006 for 24 hours and subjected to fl ow cytometry. The percentages of cells 
in the sub-G 1 (apoptotic), G 0 /G 1 , S, and G 2 /M compartments are indicated. 
Means of three independent experiments, each performed in duplicate, and 95% 
confi dence intervals are shown. 
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95% CI = 40  × 10 4 to 52  × 10 4 , versus 261  × 10 4 , 95% CI = 222.5  × 
10 4 to 300  × 10 4 ;  P <.001). Similarly, fewer RET/V804M cells 
remained after 9 days of treatment with 0.1  μ M BAY 43-9006 
than with vehicle (40.2  × 10 4 , 95% CI = 38  × 10 4 to 42.5  × 10 4 
versus 133  × 10 4 , 95% CI = 124  × 10 4 to 142  × 10 4 ;  P <.001). The 
proliferation of RAT1 fi broblasts expressing either RET/C634R 
or RET/V804M was virtually abrogated after treatment with 
1  μ M BAY 43-9006 ( Fig. 5 , D). 
 Inhibition of TT-Induced Tumor Growth in Nude Mice 
by BAY 43-9006 
 To investigate the effects of BAY 43-9006 on medullary thy-
roid carcinoma tumor growth, we injected nude mice (subcuta-
neous, right dorsal) with 1 × 10 7 TT cells. After approximately 
30 days, when tumors measured approximately 80 mm 3 , mice 
(seven in each group) were randomized to receive BAY 43-9006 
(60 mg/kg/day) or vehicle 5 days/week for 3 weeks. Treatment 
with BAY 43-9006 strongly reduced tumor growth ( Fig. 6 ). 
After 21 days, the mean volume of tumors in mice treated with 
BAY 43-9006 decreased (from 72.5 to 44 mm 3 , difference = 
28.5 mm 3 , 95% CI = 7 mm 3 to 50 mm 3 ;  P = .018), whereas that 
of mice treated with vehicle increased (from 87 to 408 mm 3 , dif-
ference = 320 mm 3 , 95% CI = 180 mm 3 to 460 mm 3 ;  P <.001) 
( Fig. 6 , A). Analysis of variance (linear mixed-effect model) test 
for repeated measures and the Wilcoxon rank-sum test demon-
strated that differences between treated and untreated animal 
were statistically signifi cant ( P <.001 and  P = .02, respectively). 
Treated tumors showed a cytoreduction, probably because of the 
extensive necrosis occurring upon treatment ( Fig. 6 , B). Ki67/
MIB-1 immunostaining was reduced in treated tumors, which is 
consistent with a reduced mitotic index (not shown). More 
 important, we observed a strong reduction of in vivo RET phos-
phorylation in proteins that were extracted from tumors in BAY 
43-9006-treated versus vehicle-treated mice ( Fig. 6 , C). 
 D ISCUSSION 
 Here, we have shown that BAY 43-9006 inhibits RET 
 enzymatic function. It inhibited RET signaling and growth of 
RET-transfected fi broblasts and human thyroid cancer cells that 
harbor RET/PTC and RET/MEN 2 oncogenes. Furthermore, 
BAY 43-9006 blocked growth of xenograft tumors that were 
 derived from a MTC cell line. 
 Fig. 5.  Inhibition of RET mutants in transformed RAT1 cells by BAY 43-9006. 
 A ) Schematic representation of RET/V804L, RET/V804M, and RET/C634R mu-
tants. EC = extracellular domain; IC = intracellular domain; TM = transmembrane 
domain.  B ) In vitro poly-( L -glutamic acid- L -tyrosine (poly-GT) phosphorylation 
assay. Proteins from RAT1 cells expressing the indicated constructs were 
immunoprecipitated with rabbit polyclonal anti-RET antibody and subjected to the 
poly-GT kinase assay. The means of results from four independent experiments 
were averaged and reported as residual poly-GT phosphorylation levels compared 
with the control (dimethyl sulfoxide [DMSO]).  C ) Protein extracts from RAT1 
cells expressing the indicated constructs and treated for 2 hours with DMSO, 
BAY 43-9006, or PP1 were immunoblotted with rabbit polyclonal anti-phospho-
RET or anti-RET antibodies.  D ) RAT1 cells expressing the indicated constructs 
were incubated with DMSO, BAY 43-9006, or PP1 in 1% serum and counted at 
different time points. Each  point represents the mean value of fi ve replicates and 
 error bars represent 95% confi dence intervals.  P values were determined using 
the two-tailed unpaired Student’s  t test. * P <.001. 
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 BAY 43-9006 is a biaryl urea that targets the RAF family 
 serine/threonine kinases RAF-1 and BRAF  ( 29 , 30 ) and the tyrosine 
kinase receptors VEGFR2 (KDR), VEGFR3 (Flt-4), Flt3, PDG-
FRB, and KIT  ( 30 ) . BAY 43-9006 probably inhibits the growth 
of RET-driven tumors through a combination of these activities 
and targets both VEGF-dependent tumor angiogenesis and RET-
dependent thyroid cancer cell proliferation. Intriguingly, the 
 anilinoquinazoline ZD6474 also exerts both anti-RET  ( 14 ) and 
anti-VEGFR activities  ( 38 ) . 
 Molecular resistance is the major obstacle to targeted cancer 
therapy with small-molecule kinase inhibitors  ( 24 ) . For example, 
relapses after an initial response are frequent in chronic myeloge-
nous leukemia due to the emergence of cells that are resistant to 
imatinib  ( 39 , 40 ) . This resistance is primarily mediated by muta-
tions that either 1) allosterically prevent the ABL kinase from 
adopting the inactive conformation to which imatinib binds or 
2) directly target the imatinib binding site. An example of the sec-
ond type of mutation is the threonine-to-isoleucine substitution 
at position 315 in ABL (T315I)  ( 39 – 42 ) . Consequently, threonine 
315 in ABL and the homologous residues in other receptor 
tyrosine kinases (threonine 790 in EGFR, threonine 674 in PDG-
FRA, and threonine 670 in KIT) have been designated  “ gate-
 keepers, ” because their mutation causes resistance to various 
small-molecule inhibitors  ( 25 – 28 ) . The homologous residue in 
RET is V804, which is a determinant of susceptibility to pyrazo-
lopyrimidines and anilinoquinazolines  ( 16 ) . Here we show that 
V804L and V804M only slightly (a two- and threefold increase in 
IC 50 , respectively) affect RET susceptibility to BAY 43-9006. 
These fi ndings also raise the possibility that BAY 43-9006 might 
be of benefi t in patients who harbor RET mutations at V804 [rare 
MEN 2 families and some sporadic medullary thyroid carcinoma 
patients  ( 4 – 5 , 17 – 23 ) ], who thus might have a  “ primary ”  resistance 
to other inhibitors. Structural analysis of BAY 43-9006 binding 
to the RET kinase would give insight as how to design inhibitors 
that can overcome drug resistance toward gate-keeper mutants. 
 The study has several potential limitations. Given the lack of 
a V804 mutation-positive MTC cell line, we could not verify 
the in vivo activity of BAY 43-9006 on this oncogenic form 
of RET. Also we cannot exclude the possibility that RET mutants, 
other than those tested in this study, may have resistance to 
the compound. 
 In conclusion, we have shown that BAY 43-9006 targets 
RET-derived oncoproteins and blocks the growth of MTC xeno-
grafts. Moreover we have shown the effi cacy of the compound 
on V804-resistant mutants. The preclinical fi ndings reported 
here suggest that BAY 43-9006 might offer a potential treatment 
strategy for papillary and medullary thyroid carcinomas sustain-
ing oncogenic activation of RET. Nevertheless, only by testing 
the activity of the compound in thyroid cancer patients will 
it be possible to assess the clinical value of RET inhibition by 
BAY 43-9006. 
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